Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer.

Female Humans Antibodies, Monoclonal, Humanized / administration & dosage Antineoplastic Combined Chemotherapy Protocols / adverse effects Carboplatin / administration & dosage DNA Mismatch Repair Double-Blind Method Endometrial Neoplasms / drug therapy Immune Checkpoint Inhibitors / administration & dosage Microsatellite Instability Neoplasm Recurrence, Local / drug therapy Paclitaxel / administration & dosage

Journal

The New England journal of medicine
ISSN: 1533-4406
Titre abrégé: N Engl J Med
Pays: United States
ID NLM: 0255562

Informations de publication

Date de publication:
08 06 2023
Historique:
medline: 9 6 2023
pubmed: 28 3 2023
entrez: 27 3 2023
Statut: ppublish

Résumé

Dostarlimab is an immune-checkpoint inhibitor that targets the programmed cell death 1 receptor. The combination of chemotherapy and immunotherapy may have synergistic effects in the treatment of endometrial cancer. We conducted a phase 3, global, double-blind, randomized, placebo-controlled trial. Eligible patients with primary advanced stage III or IV or first recurrent endometrial cancer were randomly assigned in a 1:1 ratio to receive either dostarlimab (500 mg) or placebo, plus carboplatin (area under the concentration-time curve, 5 mg per milliliter per minute) and paclitaxel (175 mg per square meter of body-surface area), every 3 weeks (six cycles), followed by dostarlimab (1000 mg) or placebo every 6 weeks for up to 3 years. The primary end points were progression-free survival as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1, and overall survival. Safety was also assessed. Of the 494 patients who underwent randomization, 118 (23.9%) had mismatch repair-deficient (dMMR), microsatellite instability-high (MSI-H) tumors. In the dMMR-MSI-H population, estimated progression-free survival at 24 months was 61.4% (95% confidence interval [CI], 46.3 to 73.4) in the dostarlimab group and 15.7% (95% CI, 7.2 to 27.0) in the placebo group (hazard ratio for progression or death, 0.28; 95% CI, 0.16 to 0.50; P<0.001). In the overall population, progression-free survival at 24 months was 36.1% (95% CI, 29.3 to 42.9) in the dostarlimab group and 18.1% (95% CI, 13.0 to 23.9) in the placebo group (hazard ratio, 0.64; 95% CI, 0.51 to 0.80; P<0.001). Overall survival at 24 months was 71.3% (95% CI, 64.5 to 77.1) with dostarlimab and 56.0% (95% CI, 48.9 to 62.5) with placebo (hazard ratio for death, 0.64; 95% CI, 0.46 to 0.87). The most common adverse events that occurred or worsened during treatment were nausea (53.9% of the patients in the dostarlimab group and 45.9% of those in the placebo group), alopecia (53.5% and 50.0%), and fatigue (51.9% and 54.5%). Severe and serious adverse events were more frequent in the dostarlimab group than in the placebo group. Dostarlimab plus carboplatin-paclitaxel significantly increased progression-free survival among patients with primary advanced or recurrent endometrial cancer, with a substantial benefit in the dMMR-MSI-H population. (Funded by GSK; RUBY ClinicalTrials.gov number, NCT03981796.).

Sections du résumé

BACKGROUND
Dostarlimab is an immune-checkpoint inhibitor that targets the programmed cell death 1 receptor. The combination of chemotherapy and immunotherapy may have synergistic effects in the treatment of endometrial cancer.
METHODS
We conducted a phase 3, global, double-blind, randomized, placebo-controlled trial. Eligible patients with primary advanced stage III or IV or first recurrent endometrial cancer were randomly assigned in a 1:1 ratio to receive either dostarlimab (500 mg) or placebo, plus carboplatin (area under the concentration-time curve, 5 mg per milliliter per minute) and paclitaxel (175 mg per square meter of body-surface area), every 3 weeks (six cycles), followed by dostarlimab (1000 mg) or placebo every 6 weeks for up to 3 years. The primary end points were progression-free survival as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1, and overall survival. Safety was also assessed.
RESULTS
Of the 494 patients who underwent randomization, 118 (23.9%) had mismatch repair-deficient (dMMR), microsatellite instability-high (MSI-H) tumors. In the dMMR-MSI-H population, estimated progression-free survival at 24 months was 61.4% (95% confidence interval [CI], 46.3 to 73.4) in the dostarlimab group and 15.7% (95% CI, 7.2 to 27.0) in the placebo group (hazard ratio for progression or death, 0.28; 95% CI, 0.16 to 0.50; P<0.001). In the overall population, progression-free survival at 24 months was 36.1% (95% CI, 29.3 to 42.9) in the dostarlimab group and 18.1% (95% CI, 13.0 to 23.9) in the placebo group (hazard ratio, 0.64; 95% CI, 0.51 to 0.80; P<0.001). Overall survival at 24 months was 71.3% (95% CI, 64.5 to 77.1) with dostarlimab and 56.0% (95% CI, 48.9 to 62.5) with placebo (hazard ratio for death, 0.64; 95% CI, 0.46 to 0.87). The most common adverse events that occurred or worsened during treatment were nausea (53.9% of the patients in the dostarlimab group and 45.9% of those in the placebo group), alopecia (53.5% and 50.0%), and fatigue (51.9% and 54.5%). Severe and serious adverse events were more frequent in the dostarlimab group than in the placebo group.
CONCLUSIONS
Dostarlimab plus carboplatin-paclitaxel significantly increased progression-free survival among patients with primary advanced or recurrent endometrial cancer, with a substantial benefit in the dMMR-MSI-H population. (Funded by GSK; RUBY ClinicalTrials.gov number, NCT03981796.).

Identifiants

DOI: 10.1056/NEJMoa2216334 PMID: 36972026
pubmed: 36972026
doi: 10.1056/NEJMoa2216334
doi:

Substances chimiques

Antibodies, Monoclonal, Humanized 0
Carboplatin BG3F62OND5
dostarlimab 0
Immune Checkpoint Inhibitors 0
Paclitaxel P88XT4IS4D

Banques de données

ClinicalTrials.gov
['NCT03981796']

Types de publication

Randomized Controlled Trial Clinical Trial, Phase III Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2145-2158

Subventions

Organisme : NCI NIH HHS
ID : UG1 CA233339
Pays : United States

Investigateurs

Mikalai Pishchyk (M)
Christine Gennigens (C)
Greet Huygh (G)
Lucy Gilbert (L)
Vanessa Samouelian (V)
Johanne Weberpals (J)
Alexandra Sebastianelli (A)
Ioannis Voutsadakis (I)
David Cibula (D)
Mansoor Mirza (M)
Adam Andrzej Luczak (AA)
Nicoline Raaschou-Jensen (N)
Trine Lembrecht Jørgensen (TL)
Lene Weber-Vestermark (L)
Jørn Herrstedt (J)
Annika Auranen (A)
Sakari Hietanen (S)
Maarit Anttila (M)
Marjo Tuppurainen (M)
Martina Gropp-Meier (M)
Andreas Hartkopf (A)
Eva-Maria Grischke (EM)
Lars Hanker (L)
Antje Lehnert (A)
Dirk Bauerschlag (D)
Dominik Denschlag (D)
Beyhan Ataseven (B)
Thomas Papathemelis (T)
George Fountzilas (G)
Andrea Bagaméri (A)
Daliah Tsoref (D)
Tamar Safra (T)
Mihai Meirovitz (M)
Yakir Segev (Y)
Shani Breuer (S)
Francesco Raspagliesi (F)
Graziana Ronzino (G)
Giorgio Valabrega (G)
Elena Geuna (E)
Antonella Savarese (A)
Fabrizio Artioli (F)
Laura Lombardo (L)
Laura Zavallone (L)
Massimiliano Nicolini (M)
Roberto Angioli (R)
Ingrid Boere (I)
Roy Lalisang (R)
Anna Reyners (A)
Machteld Wymenga (M)
Annemarie Thijs (A)
Line Bjørge (L)
Kristina Lindemann (K)
Elisabeth Berge Nilsen (E)
Anne Gry Bentzen (AG)
Guro Aune (G)
Aneta Cymbaluk-Płoska (A)
Beata Maćkowiak-Matejczyk (B)
Caroline Lundgren (C)
Magnus Frödin-Bolling (M)
Rebecca Kristeleit (R)
Anthoula Koliadi (A)
Gabriel Lindahl (G)
Fuat Demirkiran (F)
Ilhan Hacibekiroglu (I)
Mehmet Coskun Salman (MC)
Levent Yasar (L)
Vladyslav Sukhin (V)
Oleksandr Zub (O)
Joo Ern Ang (JE)
Gemma Eminowicz (G)
Rebecca Herbertson (R)
Steven Waggoner (S)
Amy Armstrong (A)
Robert Morris (R)
Radhika Gogoi (R)
David Bender (D)
Guilherme Cantuaria (G)
Christina Chu (C)
Michael Callahan (M)
Mark S Shahin (MS)
Patricia Braly (P)
Tashanna Myers (T)
Cara Mathews (C)
Robert Holloway (R)
Kari Ring (K)
Nicole Nevadunsky (N)
Bhavana Pothuri (B)
Elisabeth Driver (E)
Jonathan Berek (J)
Sarah Gill (S)
Matthew Schlumbrecht (M)
Oladapo Yeku (O)
Sara Bouberhan (S)
Matthew Powell (M)
Kathryn Pennington (K)
Angeles Secord (A)
Sudarshan Sharma (S)
Michael Teneriello (M)
Helen Eshed (H)
Rachel Miller (R)
Evelyn Fleming (E)
Carolyn Matthews (C)
Brandon Sawyer (B)
David Iglesias (D)
Eirwen Miller (E)
Caroline Billingsley (C)
Joyce Barlin (J)
Destin Black (D)
Julian Schink (J)
Barbara Buttin (B)
Kellie Schneider (K)
Jonathan Boone (J)
Michael A Gold (MA)
Jeanne Schilder (J)
Paul Mayor (P)
Lisa Landrum (L)
Paul Nowicki (P)
Sharad Ghamande (S)
Dana Chase (D)
Joseph Buscema (J)
Noelle Cloven (N)
John Diaz (J)
Alberto Mendivil (A)
Iwona Podzielinski (I)
Joshua Trinidad (J)
Floor Backes (F)

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2023 Massachusetts Medical Society.

Auteurs

Mansoor R Mirza (MR)

From the Department of Oncology, Rigshospitalet, Copenhagen University Hospital, and the Nordic Society of Gynaecological Oncology-Clinical Trial Unit, Copenhagen (M.R.M.), and the Research Unit for General Practice, University of Southern Denmark, Institute of Public Health, Odense (R.C.) - all in Denmark; David Geffen School of Medicine, University of California, Los Angeles, Los Angeles (D.M.C.); the Department of Gynecologic Oncology, Mount Sinai Medical Center, and the Department of Obstetrics and Gynecology, Florida International University, Miami Beach (B.M.S.); the Department of Gynecology, Hungarian National Institute of Oncology, Budapest, Hungary (Z.N.); the Department of Obstetrics and Gynecology, Louisiana State University Health Shreveport, and Willis-Knighton Physician Network, Shreveport (D.B.); the Division of Gynecologic Oncology, McGill University Health Centre, Montreal (L.G.); the Department of Obstetrics and Gynecology, AMITA Adventist Hinsdale Hospital, Hinsdale, IL (S.S.); the University of Turin, A.O. Ordine Mauriziano, Turin (G.V.), and the Gynecologic Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori-Milano, University of Milan, Milan (F.R.) - both in Italy; Indiana University Health Simon Cancer Center, Indianapolis (L.M.L.); the Department of Gynecology and Obstetrics, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany (L.C.H.); Women and Infants Hospital, Providence, RI (A.S.); the Department of Medical Oncology, Erasmus MC Cancer Center, Rotterdam, the Netherlands (I.B.); Oklahoma Cancer Specialists and Research Institute, Tulsa (M.A.G.); Tays Cancer Center and FICAN Mid, Tampere University and Tampere University Hospital, Tampere, Finland (A.A.); New York University Langone Health, New York (B.P.); the Department of Obstetrics and Gynecology, General University Hospital in Prague, First Faculty of Medicine, Charles University, Prague, Czech Republic (D.C.); the Division of Gynecologic Oncology (C.M.) and National Cancer Institute-sponsored NRG Oncology (M.A.P.), Washington University School of Medicine, St. Louis; Hanjani Institute for Gynecologic Oncology, Abington Hospital-Jefferson Health, Asplundh Cancer Pavilion, Sidney Kimmel Medical College, Thomas Jefferson University, Willow Grove (M.S.S.), and GSK, Collegeville (M.T., Z.H.) - both in Pennsylvania; the Division of Gynecologic Oncology, Nancy N. and J.C. Lewis Cancer and Research Pavilion, Savannah, GA (S.E.G.); HonorHealth Research Institute, University of Arizona College of Medicine, and Creighton University School of Medicine, Phoenix (B.J.M.), and the Department of Gynecologic Oncology, Arizona Oncology, Tucson (J.B.); the Department of Obstetrics and Gynecology, University of Cincinnati Cancer Center, Cincinnati (T.J.H.), and Ohio State University Comprehensive Cancer Center, Hillard (L.J.C.); GSK, London (S.S., E.Z.); and US Oncology Research, the Woodlands, TX (R.L.C.).

Dana M Chase (DM)

From the Department of Oncology, Rigshospitalet, Copenhagen University Hospital, and the Nordic Society of Gynaecological Oncology-Clinical Trial Unit, Copenhagen (M.R.M.), and the Research Unit for General Practice, University of Southern Denmark, Institute of Public Health, Odense (R.C.) - all in Denmark; David Geffen School of Medicine, University of California, Los Angeles, Los Angeles (D.M.C.); the Department of Gynecologic Oncology, Mount Sinai Medical Center, and the Department of Obstetrics and Gynecology, Florida International University, Miami Beach (B.M.S.); the Department of Gynecology, Hungarian National Institute of Oncology, Budapest, Hungary (Z.N.); the Department of Obstetrics and Gynecology, Louisiana State University Health Shreveport, and Willis-Knighton Physician Network, Shreveport (D.B.); the Division of Gynecologic Oncology, McGill University Health Centre, Montreal (L.G.); the Department of Obstetrics and Gynecology, AMITA Adventist Hinsdale Hospital, Hinsdale, IL (S.S.); the University of Turin, A.O. Ordine Mauriziano, Turin (G.V.), and the Gynecologic Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori-Milano, University of Milan, Milan (F.R.) - both in Italy; Indiana University Health Simon Cancer Center, Indianapolis (L.M.L.); the Department of Gynecology and Obstetrics, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany (L.C.H.); Women and Infants Hospital, Providence, RI (A.S.); the Department of Medical Oncology, Erasmus MC Cancer Center, Rotterdam, the Netherlands (I.B.); Oklahoma Cancer Specialists and Research Institute, Tulsa (M.A.G.); Tays Cancer Center and FICAN Mid, Tampere University and Tampere University Hospital, Tampere, Finland (A.A.); New York University Langone Health, New York (B.P.); the Department of Obstetrics and Gynecology, General University Hospital in Prague, First Faculty of Medicine, Charles University, Prague, Czech Republic (D.C.); the Division of Gynecologic Oncology (C.M.) and National Cancer Institute-sponsored NRG Oncology (M.A.P.), Washington University School of Medicine, St. Louis; Hanjani Institute for Gynecologic Oncology, Abington Hospital-Jefferson Health, Asplundh Cancer Pavilion, Sidney Kimmel Medical College, Thomas Jefferson University, Willow Grove (M.S.S.), and GSK, Collegeville (M.T., Z.H.) - both in Pennsylvania; the Division of Gynecologic Oncology, Nancy N. and J.C. Lewis Cancer and Research Pavilion, Savannah, GA (S.E.G.); HonorHealth Research Institute, University of Arizona College of Medicine, and Creighton University School of Medicine, Phoenix (B.J.M.), and the Department of Gynecologic Oncology, Arizona Oncology, Tucson (J.B.); the Department of Obstetrics and Gynecology, University of Cincinnati Cancer Center, Cincinnati (T.J.H.), and Ohio State University Comprehensive Cancer Center, Hillard (L.J.C.); GSK, London (S.S., E.Z.); and US Oncology Research, the Woodlands, TX (R.L.C.).

Brian M Slomovitz (BM)

From the Department of Oncology, Rigshospitalet, Copenhagen University Hospital, and the Nordic Society of Gynaecological Oncology-Clinical Trial Unit, Copenhagen (M.R.M.), and the Research Unit for General Practice, University of Southern Denmark, Institute of Public Health, Odense (R.C.) - all in Denmark; David Geffen School of Medicine, University of California, Los Angeles, Los Angeles (D.M.C.); the Department of Gynecologic Oncology, Mount Sinai Medical Center, and the Department of Obstetrics and Gynecology, Florida International University, Miami Beach (B.M.S.); the Department of Gynecology, Hungarian National Institute of Oncology, Budapest, Hungary (Z.N.); the Department of Obstetrics and Gynecology, Louisiana State University Health Shreveport, and Willis-Knighton Physician Network, Shreveport (D.B.); the Division of Gynecologic Oncology, McGill University Health Centre, Montreal (L.G.); the Department of Obstetrics and Gynecology, AMITA Adventist Hinsdale Hospital, Hinsdale, IL (S.S.); the University of Turin, A.O. Ordine Mauriziano, Turin (G.V.), and the Gynecologic Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori-Milano, University of Milan, Milan (F.R.) - both in Italy; Indiana University Health Simon Cancer Center, Indianapolis (L.M.L.); the Department of Gynecology and Obstetrics, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany (L.C.H.); Women and Infants Hospital, Providence, RI (A.S.); the Department of Medical Oncology, Erasmus MC Cancer Center, Rotterdam, the Netherlands (I.B.); Oklahoma Cancer Specialists and Research Institute, Tulsa (M.A.G.); Tays Cancer Center and FICAN Mid, Tampere University and Tampere University Hospital, Tampere, Finland (A.A.); New York University Langone Health, New York (B.P.); the Department of Obstetrics and Gynecology, General University Hospital in Prague, First Faculty of Medicine, Charles University, Prague, Czech Republic (D.C.); the Division of Gynecologic Oncology (C.M.) and National Cancer Institute-sponsored NRG Oncology (M.A.P.), Washington University School of Medicine, St. Louis; Hanjani Institute for Gynecologic Oncology, Abington Hospital-Jefferson Health, Asplundh Cancer Pavilion, Sidney Kimmel Medical College, Thomas Jefferson University, Willow Grove (M.S.S.), and GSK, Collegeville (M.T., Z.H.) - both in Pennsylvania; the Division of Gynecologic Oncology, Nancy N. and J.C. Lewis Cancer and Research Pavilion, Savannah, GA (S.E.G.); HonorHealth Research Institute, University of Arizona College of Medicine, and Creighton University School of Medicine, Phoenix (B.J.M.), and the Department of Gynecologic Oncology, Arizona Oncology, Tucson (J.B.); the Department of Obstetrics and Gynecology, University of Cincinnati Cancer Center, Cincinnati (T.J.H.), and Ohio State University Comprehensive Cancer Center, Hillard (L.J.C.); GSK, London (S.S., E.Z.); and US Oncology Research, the Woodlands, TX (R.L.C.).

René dePont Christensen (R)

From the Department of Oncology, Rigshospitalet, Copenhagen University Hospital, and the Nordic Society of Gynaecological Oncology-Clinical Trial Unit, Copenhagen (M.R.M.), and the Research Unit for General Practice, University of Southern Denmark, Institute of Public Health, Odense (R.C.) - all in Denmark; David Geffen School of Medicine, University of California, Los Angeles, Los Angeles (D.M.C.); the Department of Gynecologic Oncology, Mount Sinai Medical Center, and the Department of Obstetrics and Gynecology, Florida International University, Miami Beach (B.M.S.); the Department of Gynecology, Hungarian National Institute of Oncology, Budapest, Hungary (Z.N.); the Department of Obstetrics and Gynecology, Louisiana State University Health Shreveport, and Willis-Knighton Physician Network, Shreveport (D.B.); the Division of Gynecologic Oncology, McGill University Health Centre, Montreal (L.G.); the Department of Obstetrics and Gynecology, AMITA Adventist Hinsdale Hospital, Hinsdale, IL (S.S.); the University of Turin, A.O. Ordine Mauriziano, Turin (G.V.), and the Gynecologic Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori-Milano, University of Milan, Milan (F.R.) - both in Italy; Indiana University Health Simon Cancer Center, Indianapolis (L.M.L.); the Department of Gynecology and Obstetrics, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany (L.C.H.); Women and Infants Hospital, Providence, RI (A.S.); the Department of Medical Oncology, Erasmus MC Cancer Center, Rotterdam, the Netherlands (I.B.); Oklahoma Cancer Specialists and Research Institute, Tulsa (M.A.G.); Tays Cancer Center and FICAN Mid, Tampere University and Tampere University Hospital, Tampere, Finland (A.A.); New York University Langone Health, New York (B.P.); the Department of Obstetrics and Gynecology, General University Hospital in Prague, First Faculty of Medicine, Charles University, Prague, Czech Republic (D.C.); the Division of Gynecologic Oncology (C.M.) and National Cancer Institute-sponsored NRG Oncology (M.A.P.), Washington University School of Medicine, St. Louis; Hanjani Institute for Gynecologic Oncology, Abington Hospital-Jefferson Health, Asplundh Cancer Pavilion, Sidney Kimmel Medical College, Thomas Jefferson University, Willow Grove (M.S.S.), and GSK, Collegeville (M.T., Z.H.) - both in Pennsylvania; the Division of Gynecologic Oncology, Nancy N. and J.C. Lewis Cancer and Research Pavilion, Savannah, GA (S.E.G.); HonorHealth Research Institute, University of Arizona College of Medicine, and Creighton University School of Medicine, Phoenix (B.J.M.), and the Department of Gynecologic Oncology, Arizona Oncology, Tucson (J.B.); the Department of Obstetrics and Gynecology, University of Cincinnati Cancer Center, Cincinnati (T.J.H.), and Ohio State University Comprehensive Cancer Center, Hillard (L.J.C.); GSK, London (S.S., E.Z.); and US Oncology Research, the Woodlands, TX (R.L.C.).

Zoltán Novák (Z)

From the Department of Oncology, Rigshospitalet, Copenhagen University Hospital, and the Nordic Society of Gynaecological Oncology-Clinical Trial Unit, Copenhagen (M.R.M.), and the Research Unit for General Practice, University of Southern Denmark, Institute of Public Health, Odense (R.C.) - all in Denmark; David Geffen School of Medicine, University of California, Los Angeles, Los Angeles (D.M.C.); the Department of Gynecologic Oncology, Mount Sinai Medical Center, and the Department of Obstetrics and Gynecology, Florida International University, Miami Beach (B.M.S.); the Department of Gynecology, Hungarian National Institute of Oncology, Budapest, Hungary (Z.N.); the Department of Obstetrics and Gynecology, Louisiana State University Health Shreveport, and Willis-Knighton Physician Network, Shreveport (D.B.); the Division of Gynecologic Oncology, McGill University Health Centre, Montreal (L.G.); the Department of Obstetrics and Gynecology, AMITA Adventist Hinsdale Hospital, Hinsdale, IL (S.S.); the University of Turin, A.O. Ordine Mauriziano, Turin (G.V.), and the Gynecologic Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori-Milano, University of Milan, Milan (F.R.) - both in Italy; Indiana University Health Simon Cancer Center, Indianapolis (L.M.L.); the Department of Gynecology and Obstetrics, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany (L.C.H.); Women and Infants Hospital, Providence, RI (A.S.); the Department of Medical Oncology, Erasmus MC Cancer Center, Rotterdam, the Netherlands (I.B.); Oklahoma Cancer Specialists and Research Institute, Tulsa (M.A.G.); Tays Cancer Center and FICAN Mid, Tampere University and Tampere University Hospital, Tampere, Finland (A.A.); New York University Langone Health, New York (B.P.); the Department of Obstetrics and Gynecology, General University Hospital in Prague, First Faculty of Medicine, Charles University, Prague, Czech Republic (D.C.); the Division of Gynecologic Oncology (C.M.) and National Cancer Institute-sponsored NRG Oncology (M.A.P.), Washington University School of Medicine, St. Louis; Hanjani Institute for Gynecologic Oncology, Abington Hospital-Jefferson Health, Asplundh Cancer Pavilion, Sidney Kimmel Medical College, Thomas Jefferson University, Willow Grove (M.S.S.), and GSK, Collegeville (M.T., Z.H.) - both in Pennsylvania; the Division of Gynecologic Oncology, Nancy N. and J.C. Lewis Cancer and Research Pavilion, Savannah, GA (S.E.G.); HonorHealth Research Institute, University of Arizona College of Medicine, and Creighton University School of Medicine, Phoenix (B.J.M.), and the Department of Gynecologic Oncology, Arizona Oncology, Tucson (J.B.); the Department of Obstetrics and Gynecology, University of Cincinnati Cancer Center, Cincinnati (T.J.H.), and Ohio State University Comprehensive Cancer Center, Hillard (L.J.C.); GSK, London (S.S., E.Z.); and US Oncology Research, the Woodlands, TX (R.L.C.).

Destin Black (D)

From the Department of Oncology, Rigshospitalet, Copenhagen University Hospital, and the Nordic Society of Gynaecological Oncology-Clinical Trial Unit, Copenhagen (M.R.M.), and the Research Unit for General Practice, University of Southern Denmark, Institute of Public Health, Odense (R.C.) - all in Denmark; David Geffen School of Medicine, University of California, Los Angeles, Los Angeles (D.M.C.); the Department of Gynecologic Oncology, Mount Sinai Medical Center, and the Department of Obstetrics and Gynecology, Florida International University, Miami Beach (B.M.S.); the Department of Gynecology, Hungarian National Institute of Oncology, Budapest, Hungary (Z.N.); the Department of Obstetrics and Gynecology, Louisiana State University Health Shreveport, and Willis-Knighton Physician Network, Shreveport (D.B.); the Division of Gynecologic Oncology, McGill University Health Centre, Montreal (L.G.); the Department of Obstetrics and Gynecology, AMITA Adventist Hinsdale Hospital, Hinsdale, IL (S.S.); the University of Turin, A.O. Ordine Mauriziano, Turin (G.V.), and the Gynecologic Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori-Milano, University of Milan, Milan (F.R.) - both in Italy; Indiana University Health Simon Cancer Center, Indianapolis (L.M.L.); the Department of Gynecology and Obstetrics, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany (L.C.H.); Women and Infants Hospital, Providence, RI (A.S.); the Department of Medical Oncology, Erasmus MC Cancer Center, Rotterdam, the Netherlands (I.B.); Oklahoma Cancer Specialists and Research Institute, Tulsa (M.A.G.); Tays Cancer Center and FICAN Mid, Tampere University and Tampere University Hospital, Tampere, Finland (A.A.); New York University Langone Health, New York (B.P.); the Department of Obstetrics and Gynecology, General University Hospital in Prague, First Faculty of Medicine, Charles University, Prague, Czech Republic (D.C.); the Division of Gynecologic Oncology (C.M.) and National Cancer Institute-sponsored NRG Oncology (M.A.P.), Washington University School of Medicine, St. Louis; Hanjani Institute for Gynecologic Oncology, Abington Hospital-Jefferson Health, Asplundh Cancer Pavilion, Sidney Kimmel Medical College, Thomas Jefferson University, Willow Grove (M.S.S.), and GSK, Collegeville (M.T., Z.H.) - both in Pennsylvania; the Division of Gynecologic Oncology, Nancy N. and J.C. Lewis Cancer and Research Pavilion, Savannah, GA (S.E.G.); HonorHealth Research Institute, University of Arizona College of Medicine, and Creighton University School of Medicine, Phoenix (B.J.M.), and the Department of Gynecologic Oncology, Arizona Oncology, Tucson (J.B.); the Department of Obstetrics and Gynecology, University of Cincinnati Cancer Center, Cincinnati (T.J.H.), and Ohio State University Comprehensive Cancer Center, Hillard (L.J.C.); GSK, London (S.S., E.Z.); and US Oncology Research, the Woodlands, TX (R.L.C.).

Lucy Gilbert (L)

From the Department of Oncology, Rigshospitalet, Copenhagen University Hospital, and the Nordic Society of Gynaecological Oncology-Clinical Trial Unit, Copenhagen (M.R.M.), and the Research Unit for General Practice, University of Southern Denmark, Institute of Public Health, Odense (R.C.) - all in Denmark; David Geffen School of Medicine, University of California, Los Angeles, Los Angeles (D.M.C.); the Department of Gynecologic Oncology, Mount Sinai Medical Center, and the Department of Obstetrics and Gynecology, Florida International University, Miami Beach (B.M.S.); the Department of Gynecology, Hungarian National Institute of Oncology, Budapest, Hungary (Z.N.); the Department of Obstetrics and Gynecology, Louisiana State University Health Shreveport, and Willis-Knighton Physician Network, Shreveport (D.B.); the Division of Gynecologic Oncology, McGill University Health Centre, Montreal (L.G.); the Department of Obstetrics and Gynecology, AMITA Adventist Hinsdale Hospital, Hinsdale, IL (S.S.); the University of Turin, A.O. Ordine Mauriziano, Turin (G.V.), and the Gynecologic Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori-Milano, University of Milan, Milan (F.R.) - both in Italy; Indiana University Health Simon Cancer Center, Indianapolis (L.M.L.); the Department of Gynecology and Obstetrics, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany (L.C.H.); Women and Infants Hospital, Providence, RI (A.S.); the Department of Medical Oncology, Erasmus MC Cancer Center, Rotterdam, the Netherlands (I.B.); Oklahoma Cancer Specialists and Research Institute, Tulsa (M.A.G.); Tays Cancer Center and FICAN Mid, Tampere University and Tampere University Hospital, Tampere, Finland (A.A.); New York University Langone Health, New York (B.P.); the Department of Obstetrics and Gynecology, General University Hospital in Prague, First Faculty of Medicine, Charles University, Prague, Czech Republic (D.C.); the Division of Gynecologic Oncology (C.M.) and National Cancer Institute-sponsored NRG Oncology (M.A.P.), Washington University School of Medicine, St. Louis; Hanjani Institute for Gynecologic Oncology, Abington Hospital-Jefferson Health, Asplundh Cancer Pavilion, Sidney Kimmel Medical College, Thomas Jefferson University, Willow Grove (M.S.S.), and GSK, Collegeville (M.T., Z.H.) - both in Pennsylvania; the Division of Gynecologic Oncology, Nancy N. and J.C. Lewis Cancer and Research Pavilion, Savannah, GA (S.E.G.); HonorHealth Research Institute, University of Arizona College of Medicine, and Creighton University School of Medicine, Phoenix (B.J.M.), and the Department of Gynecologic Oncology, Arizona Oncology, Tucson (J.B.); the Department of Obstetrics and Gynecology, University of Cincinnati Cancer Center, Cincinnati (T.J.H.), and Ohio State University Comprehensive Cancer Center, Hillard (L.J.C.); GSK, London (S.S., E.Z.); and US Oncology Research, the Woodlands, TX (R.L.C.).

Sudarshan Sharma (S)

From the Department of Oncology, Rigshospitalet, Copenhagen University Hospital, and the Nordic Society of Gynaecological Oncology-Clinical Trial Unit, Copenhagen (M.R.M.), and the Research Unit for General Practice, University of Southern Denmark, Institute of Public Health, Odense (R.C.) - all in Denmark; David Geffen School of Medicine, University of California, Los Angeles, Los Angeles (D.M.C.); the Department of Gynecologic Oncology, Mount Sinai Medical Center, and the Department of Obstetrics and Gynecology, Florida International University, Miami Beach (B.M.S.); the Department of Gynecology, Hungarian National Institute of Oncology, Budapest, Hungary (Z.N.); the Department of Obstetrics and Gynecology, Louisiana State University Health Shreveport, and Willis-Knighton Physician Network, Shreveport (D.B.); the Division of Gynecologic Oncology, McGill University Health Centre, Montreal (L.G.); the Department of Obstetrics and Gynecology, AMITA Adventist Hinsdale Hospital, Hinsdale, IL (S.S.); the University of Turin, A.O. Ordine Mauriziano, Turin (G.V.), and the Gynecologic Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori-Milano, University of Milan, Milan (F.R.) - both in Italy; Indiana University Health Simon Cancer Center, Indianapolis (L.M.L.); the Department of Gynecology and Obstetrics, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany (L.C.H.); Women and Infants Hospital, Providence, RI (A.S.); the Department of Medical Oncology, Erasmus MC Cancer Center, Rotterdam, the Netherlands (I.B.); Oklahoma Cancer Specialists and Research Institute, Tulsa (M.A.G.); Tays Cancer Center and FICAN Mid, Tampere University and Tampere University Hospital, Tampere, Finland (A.A.); New York University Langone Health, New York (B.P.); the Department of Obstetrics and Gynecology, General University Hospital in Prague, First Faculty of Medicine, Charles University, Prague, Czech Republic (D.C.); the Division of Gynecologic Oncology (C.M.) and National Cancer Institute-sponsored NRG Oncology (M.A.P.), Washington University School of Medicine, St. Louis; Hanjani Institute for Gynecologic Oncology, Abington Hospital-Jefferson Health, Asplundh Cancer Pavilion, Sidney Kimmel Medical College, Thomas Jefferson University, Willow Grove (M.S.S.), and GSK, Collegeville (M.T., Z.H.) - both in Pennsylvania; the Division of Gynecologic Oncology, Nancy N. and J.C. Lewis Cancer and Research Pavilion, Savannah, GA (S.E.G.); HonorHealth Research Institute, University of Arizona College of Medicine, and Creighton University School of Medicine, Phoenix (B.J.M.), and the Department of Gynecologic Oncology, Arizona Oncology, Tucson (J.B.); the Department of Obstetrics and Gynecology, University of Cincinnati Cancer Center, Cincinnati (T.J.H.), and Ohio State University Comprehensive Cancer Center, Hillard (L.J.C.); GSK, London (S.S., E.Z.); and US Oncology Research, the Woodlands, TX (R.L.C.).

Giorgio Valabrega (G)

From the Department of Oncology, Rigshospitalet, Copenhagen University Hospital, and the Nordic Society of Gynaecological Oncology-Clinical Trial Unit, Copenhagen (M.R.M.), and the Research Unit for General Practice, University of Southern Denmark, Institute of Public Health, Odense (R.C.) - all in Denmark; David Geffen School of Medicine, University of California, Los Angeles, Los Angeles (D.M.C.); the Department of Gynecologic Oncology, Mount Sinai Medical Center, and the Department of Obstetrics and Gynecology, Florida International University, Miami Beach (B.M.S.); the Department of Gynecology, Hungarian National Institute of Oncology, Budapest, Hungary (Z.N.); the Department of Obstetrics and Gynecology, Louisiana State University Health Shreveport, and Willis-Knighton Physician Network, Shreveport (D.B.); the Division of Gynecologic Oncology, McGill University Health Centre, Montreal (L.G.); the Department of Obstetrics and Gynecology, AMITA Adventist Hinsdale Hospital, Hinsdale, IL (S.S.); the University of Turin, A.O. Ordine Mauriziano, Turin (G.V.), and the Gynecologic Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori-Milano, University of Milan, Milan (F.R.) - both in Italy; Indiana University Health Simon Cancer Center, Indianapolis (L.M.L.); the Department of Gynecology and Obstetrics, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany (L.C.H.); Women and Infants Hospital, Providence, RI (A.S.); the Department of Medical Oncology, Erasmus MC Cancer Center, Rotterdam, the Netherlands (I.B.); Oklahoma Cancer Specialists and Research Institute, Tulsa (M.A.G.); Tays Cancer Center and FICAN Mid, Tampere University and Tampere University Hospital, Tampere, Finland (A.A.); New York University Langone Health, New York (B.P.); the Department of Obstetrics and Gynecology, General University Hospital in Prague, First Faculty of Medicine, Charles University, Prague, Czech Republic (D.C.); the Division of Gynecologic Oncology (C.M.) and National Cancer Institute-sponsored NRG Oncology (M.A.P.), Washington University School of Medicine, St. Louis; Hanjani Institute for Gynecologic Oncology, Abington Hospital-Jefferson Health, Asplundh Cancer Pavilion, Sidney Kimmel Medical College, Thomas Jefferson University, Willow Grove (M.S.S.), and GSK, Collegeville (M.T., Z.H.) - both in Pennsylvania; the Division of Gynecologic Oncology, Nancy N. and J.C. Lewis Cancer and Research Pavilion, Savannah, GA (S.E.G.); HonorHealth Research Institute, University of Arizona College of Medicine, and Creighton University School of Medicine, Phoenix (B.J.M.), and the Department of Gynecologic Oncology, Arizona Oncology, Tucson (J.B.); the Department of Obstetrics and Gynecology, University of Cincinnati Cancer Center, Cincinnati (T.J.H.), and Ohio State University Comprehensive Cancer Center, Hillard (L.J.C.); GSK, London (S.S., E.Z.); and US Oncology Research, the Woodlands, TX (R.L.C.).

Lisa M Landrum (LM)

From the Department of Oncology, Rigshospitalet, Copenhagen University Hospital, and the Nordic Society of Gynaecological Oncology-Clinical Trial Unit, Copenhagen (M.R.M.), and the Research Unit for General Practice, University of Southern Denmark, Institute of Public Health, Odense (R.C.) - all in Denmark; David Geffen School of Medicine, University of California, Los Angeles, Los Angeles (D.M.C.); the Department of Gynecologic Oncology, Mount Sinai Medical Center, and the Department of Obstetrics and Gynecology, Florida International University, Miami Beach (B.M.S.); the Department of Gynecology, Hungarian National Institute of Oncology, Budapest, Hungary (Z.N.); the Department of Obstetrics and Gynecology, Louisiana State University Health Shreveport, and Willis-Knighton Physician Network, Shreveport (D.B.); the Division of Gynecologic Oncology, McGill University Health Centre, Montreal (L.G.); the Department of Obstetrics and Gynecology, AMITA Adventist Hinsdale Hospital, Hinsdale, IL (S.S.); the University of Turin, A.O. Ordine Mauriziano, Turin (G.V.), and the Gynecologic Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori-Milano, University of Milan, Milan (F.R.) - both in Italy; Indiana University Health Simon Cancer Center, Indianapolis (L.M.L.); the Department of Gynecology and Obstetrics, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany (L.C.H.); Women and Infants Hospital, Providence, RI (A.S.); the Department of Medical Oncology, Erasmus MC Cancer Center, Rotterdam, the Netherlands (I.B.); Oklahoma Cancer Specialists and Research Institute, Tulsa (M.A.G.); Tays Cancer Center and FICAN Mid, Tampere University and Tampere University Hospital, Tampere, Finland (A.A.); New York University Langone Health, New York (B.P.); the Department of Obstetrics and Gynecology, General University Hospital in Prague, First Faculty of Medicine, Charles University, Prague, Czech Republic (D.C.); the Division of Gynecologic Oncology (C.M.) and National Cancer Institute-sponsored NRG Oncology (M.A.P.), Washington University School of Medicine, St. Louis; Hanjani Institute for Gynecologic Oncology, Abington Hospital-Jefferson Health, Asplundh Cancer Pavilion, Sidney Kimmel Medical College, Thomas Jefferson University, Willow Grove (M.S.S.), and GSK, Collegeville (M.T., Z.H.) - both in Pennsylvania; the Division of Gynecologic Oncology, Nancy N. and J.C. Lewis Cancer and Research Pavilion, Savannah, GA (S.E.G.); HonorHealth Research Institute, University of Arizona College of Medicine, and Creighton University School of Medicine, Phoenix (B.J.M.), and the Department of Gynecologic Oncology, Arizona Oncology, Tucson (J.B.); the Department of Obstetrics and Gynecology, University of Cincinnati Cancer Center, Cincinnati (T.J.H.), and Ohio State University Comprehensive Cancer Center, Hillard (L.J.C.); GSK, London (S.S., E.Z.); and US Oncology Research, the Woodlands, TX (R.L.C.).

Lars C Hanker (LC)

From the Department of Oncology, Rigshospitalet, Copenhagen University Hospital, and the Nordic Society of Gynaecological Oncology-Clinical Trial Unit, Copenhagen (M.R.M.), and the Research Unit for General Practice, University of Southern Denmark, Institute of Public Health, Odense (R.C.) - all in Denmark; David Geffen School of Medicine, University of California, Los Angeles, Los Angeles (D.M.C.); the Department of Gynecologic Oncology, Mount Sinai Medical Center, and the Department of Obstetrics and Gynecology, Florida International University, Miami Beach (B.M.S.); the Department of Gynecology, Hungarian National Institute of Oncology, Budapest, Hungary (Z.N.); the Department of Obstetrics and Gynecology, Louisiana State University Health Shreveport, and Willis-Knighton Physician Network, Shreveport (D.B.); the Division of Gynecologic Oncology, McGill University Health Centre, Montreal (L.G.); the Department of Obstetrics and Gynecology, AMITA Adventist Hinsdale Hospital, Hinsdale, IL (S.S.); the University of Turin, A.O. Ordine Mauriziano, Turin (G.V.), and the Gynecologic Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori-Milano, University of Milan, Milan (F.R.) - both in Italy; Indiana University Health Simon Cancer Center, Indianapolis (L.M.L.); the Department of Gynecology and Obstetrics, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany (L.C.H.); Women and Infants Hospital, Providence, RI (A.S.); the Department of Medical Oncology, Erasmus MC Cancer Center, Rotterdam, the Netherlands (I.B.); Oklahoma Cancer Specialists and Research Institute, Tulsa (M.A.G.); Tays Cancer Center and FICAN Mid, Tampere University and Tampere University Hospital, Tampere, Finland (A.A.); New York University Langone Health, New York (B.P.); the Department of Obstetrics and Gynecology, General University Hospital in Prague, First Faculty of Medicine, Charles University, Prague, Czech Republic (D.C.); the Division of Gynecologic Oncology (C.M.) and National Cancer Institute-sponsored NRG Oncology (M.A.P.), Washington University School of Medicine, St. Louis; Hanjani Institute for Gynecologic Oncology, Abington Hospital-Jefferson Health, Asplundh Cancer Pavilion, Sidney Kimmel Medical College, Thomas Jefferson University, Willow Grove (M.S.S.), and GSK, Collegeville (M.T., Z.H.) - both in Pennsylvania; the Division of Gynecologic Oncology, Nancy N. and J.C. Lewis Cancer and Research Pavilion, Savannah, GA (S.E.G.); HonorHealth Research Institute, University of Arizona College of Medicine, and Creighton University School of Medicine, Phoenix (B.J.M.), and the Department of Gynecologic Oncology, Arizona Oncology, Tucson (J.B.); the Department of Obstetrics and Gynecology, University of Cincinnati Cancer Center, Cincinnati (T.J.H.), and Ohio State University Comprehensive Cancer Center, Hillard (L.J.C.); GSK, London (S.S., E.Z.); and US Oncology Research, the Woodlands, TX (R.L.C.).

Ashley Stuckey (A)

From the Department of Oncology, Rigshospitalet, Copenhagen University Hospital, and the Nordic Society of Gynaecological Oncology-Clinical Trial Unit, Copenhagen (M.R.M.), and the Research Unit for General Practice, University of Southern Denmark, Institute of Public Health, Odense (R.C.) - all in Denmark; David Geffen School of Medicine, University of California, Los Angeles, Los Angeles (D.M.C.); the Department of Gynecologic Oncology, Mount Sinai Medical Center, and the Department of Obstetrics and Gynecology, Florida International University, Miami Beach (B.M.S.); the Department of Gynecology, Hungarian National Institute of Oncology, Budapest, Hungary (Z.N.); the Department of Obstetrics and Gynecology, Louisiana State University Health Shreveport, and Willis-Knighton Physician Network, Shreveport (D.B.); the Division of Gynecologic Oncology, McGill University Health Centre, Montreal (L.G.); the Department of Obstetrics and Gynecology, AMITA Adventist Hinsdale Hospital, Hinsdale, IL (S.S.); the University of Turin, A.O. Ordine Mauriziano, Turin (G.V.), and the Gynecologic Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori-Milano, University of Milan, Milan (F.R.) - both in Italy; Indiana University Health Simon Cancer Center, Indianapolis (L.M.L.); the Department of Gynecology and Obstetrics, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany (L.C.H.); Women and Infants Hospital, Providence, RI (A.S.); the Department of Medical Oncology, Erasmus MC Cancer Center, Rotterdam, the Netherlands (I.B.); Oklahoma Cancer Specialists and Research Institute, Tulsa (M.A.G.); Tays Cancer Center and FICAN Mid, Tampere University and Tampere University Hospital, Tampere, Finland (A.A.); New York University Langone Health, New York (B.P.); the Department of Obstetrics and Gynecology, General University Hospital in Prague, First Faculty of Medicine, Charles University, Prague, Czech Republic (D.C.); the Division of Gynecologic Oncology (C.M.) and National Cancer Institute-sponsored NRG Oncology (M.A.P.), Washington University School of Medicine, St. Louis; Hanjani Institute for Gynecologic Oncology, Abington Hospital-Jefferson Health, Asplundh Cancer Pavilion, Sidney Kimmel Medical College, Thomas Jefferson University, Willow Grove (M.S.S.), and GSK, Collegeville (M.T., Z.H.) - both in Pennsylvania; the Division of Gynecologic Oncology, Nancy N. and J.C. Lewis Cancer and Research Pavilion, Savannah, GA (S.E.G.); HonorHealth Research Institute, University of Arizona College of Medicine, and Creighton University School of Medicine, Phoenix (B.J.M.), and the Department of Gynecologic Oncology, Arizona Oncology, Tucson (J.B.); the Department of Obstetrics and Gynecology, University of Cincinnati Cancer Center, Cincinnati (T.J.H.), and Ohio State University Comprehensive Cancer Center, Hillard (L.J.C.); GSK, London (S.S., E.Z.); and US Oncology Research, the Woodlands, TX (R.L.C.).

Ingrid Boere (I)

From the Department of Oncology, Rigshospitalet, Copenhagen University Hospital, and the Nordic Society of Gynaecological Oncology-Clinical Trial Unit, Copenhagen (M.R.M.), and the Research Unit for General Practice, University of Southern Denmark, Institute of Public Health, Odense (R.C.) - all in Denmark; David Geffen School of Medicine, University of California, Los Angeles, Los Angeles (D.M.C.); the Department of Gynecologic Oncology, Mount Sinai Medical Center, and the Department of Obstetrics and Gynecology, Florida International University, Miami Beach (B.M.S.); the Department of Gynecology, Hungarian National Institute of Oncology, Budapest, Hungary (Z.N.); the Department of Obstetrics and Gynecology, Louisiana State University Health Shreveport, and Willis-Knighton Physician Network, Shreveport (D.B.); the Division of Gynecologic Oncology, McGill University Health Centre, Montreal (L.G.); the Department of Obstetrics and Gynecology, AMITA Adventist Hinsdale Hospital, Hinsdale, IL (S.S.); the University of Turin, A.O. Ordine Mauriziano, Turin (G.V.), and the Gynecologic Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori-Milano, University of Milan, Milan (F.R.) - both in Italy; Indiana University Health Simon Cancer Center, Indianapolis (L.M.L.); the Department of Gynecology and Obstetrics, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany (L.C.H.); Women and Infants Hospital, Providence, RI (A.S.); the Department of Medical Oncology, Erasmus MC Cancer Center, Rotterdam, the Netherlands (I.B.); Oklahoma Cancer Specialists and Research Institute, Tulsa (M.A.G.); Tays Cancer Center and FICAN Mid, Tampere University and Tampere University Hospital, Tampere, Finland (A.A.); New York University Langone Health, New York (B.P.); the Department of Obstetrics and Gynecology, General University Hospital in Prague, First Faculty of Medicine, Charles University, Prague, Czech Republic (D.C.); the Division of Gynecologic Oncology (C.M.) and National Cancer Institute-sponsored NRG Oncology (M.A.P.), Washington University School of Medicine, St. Louis; Hanjani Institute for Gynecologic Oncology, Abington Hospital-Jefferson Health, Asplundh Cancer Pavilion, Sidney Kimmel Medical College, Thomas Jefferson University, Willow Grove (M.S.S.), and GSK, Collegeville (M.T., Z.H.) - both in Pennsylvania; the Division of Gynecologic Oncology, Nancy N. and J.C. Lewis Cancer and Research Pavilion, Savannah, GA (S.E.G.); HonorHealth Research Institute, University of Arizona College of Medicine, and Creighton University School of Medicine, Phoenix (B.J.M.), and the Department of Gynecologic Oncology, Arizona Oncology, Tucson (J.B.); the Department of Obstetrics and Gynecology, University of Cincinnati Cancer Center, Cincinnati (T.J.H.), and Ohio State University Comprehensive Cancer Center, Hillard (L.J.C.); GSK, London (S.S., E.Z.); and US Oncology Research, the Woodlands, TX (R.L.C.).

Michael A Gold (MA)

From the Department of Oncology, Rigshospitalet, Copenhagen University Hospital, and the Nordic Society of Gynaecological Oncology-Clinical Trial Unit, Copenhagen (M.R.M.), and the Research Unit for General Practice, University of Southern Denmark, Institute of Public Health, Odense (R.C.) - all in Denmark; David Geffen School of Medicine, University of California, Los Angeles, Los Angeles (D.M.C.); the Department of Gynecologic Oncology, Mount Sinai Medical Center, and the Department of Obstetrics and Gynecology, Florida International University, Miami Beach (B.M.S.); the Department of Gynecology, Hungarian National Institute of Oncology, Budapest, Hungary (Z.N.); the Department of Obstetrics and Gynecology, Louisiana State University Health Shreveport, and Willis-Knighton Physician Network, Shreveport (D.B.); the Division of Gynecologic Oncology, McGill University Health Centre, Montreal (L.G.); the Department of Obstetrics and Gynecology, AMITA Adventist Hinsdale Hospital, Hinsdale, IL (S.S.); the University of Turin, A.O. Ordine Mauriziano, Turin (G.V.), and the Gynecologic Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori-Milano, University of Milan, Milan (F.R.) - both in Italy; Indiana University Health Simon Cancer Center, Indianapolis (L.M.L.); the Department of Gynecology and Obstetrics, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany (L.C.H.); Women and Infants Hospital, Providence, RI (A.S.); the Department of Medical Oncology, Erasmus MC Cancer Center, Rotterdam, the Netherlands (I.B.); Oklahoma Cancer Specialists and Research Institute, Tulsa (M.A.G.); Tays Cancer Center and FICAN Mid, Tampere University and Tampere University Hospital, Tampere, Finland (A.A.); New York University Langone Health, New York (B.P.); the Department of Obstetrics and Gynecology, General University Hospital in Prague, First Faculty of Medicine, Charles University, Prague, Czech Republic (D.C.); the Division of Gynecologic Oncology (C.M.) and National Cancer Institute-sponsored NRG Oncology (M.A.P.), Washington University School of Medicine, St. Louis; Hanjani Institute for Gynecologic Oncology, Abington Hospital-Jefferson Health, Asplundh Cancer Pavilion, Sidney Kimmel Medical College, Thomas Jefferson University, Willow Grove (M.S.S.), and GSK, Collegeville (M.T., Z.H.) - both in Pennsylvania; the Division of Gynecologic Oncology, Nancy N. and J.C. Lewis Cancer and Research Pavilion, Savannah, GA (S.E.G.); HonorHealth Research Institute, University of Arizona College of Medicine, and Creighton University School of Medicine, Phoenix (B.J.M.), and the Department of Gynecologic Oncology, Arizona Oncology, Tucson (J.B.); the Department of Obstetrics and Gynecology, University of Cincinnati Cancer Center, Cincinnati (T.J.H.), and Ohio State University Comprehensive Cancer Center, Hillard (L.J.C.); GSK, London (S.S., E.Z.); and US Oncology Research, the Woodlands, TX (R.L.C.).

Annika Auranen (A)

From the Department of Oncology, Rigshospitalet, Copenhagen University Hospital, and the Nordic Society of Gynaecological Oncology-Clinical Trial Unit, Copenhagen (M.R.M.), and the Research Unit for General Practice, University of Southern Denmark, Institute of Public Health, Odense (R.C.) - all in Denmark; David Geffen School of Medicine, University of California, Los Angeles, Los Angeles (D.M.C.); the Department of Gynecologic Oncology, Mount Sinai Medical Center, and the Department of Obstetrics and Gynecology, Florida International University, Miami Beach (B.M.S.); the Department of Gynecology, Hungarian National Institute of Oncology, Budapest, Hungary (Z.N.); the Department of Obstetrics and Gynecology, Louisiana State University Health Shreveport, and Willis-Knighton Physician Network, Shreveport (D.B.); the Division of Gynecologic Oncology, McGill University Health Centre, Montreal (L.G.); the Department of Obstetrics and Gynecology, AMITA Adventist Hinsdale Hospital, Hinsdale, IL (S.S.); the University of Turin, A.O. Ordine Mauriziano, Turin (G.V.), and the Gynecologic Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori-Milano, University of Milan, Milan (F.R.) - both in Italy; Indiana University Health Simon Cancer Center, Indianapolis (L.M.L.); the Department of Gynecology and Obstetrics, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany (L.C.H.); Women and Infants Hospital, Providence, RI (A.S.); the Department of Medical Oncology, Erasmus MC Cancer Center, Rotterdam, the Netherlands (I.B.); Oklahoma Cancer Specialists and Research Institute, Tulsa (M.A.G.); Tays Cancer Center and FICAN Mid, Tampere University and Tampere University Hospital, Tampere, Finland (A.A.); New York University Langone Health, New York (B.P.); the Department of Obstetrics and Gynecology, General University Hospital in Prague, First Faculty of Medicine, Charles University, Prague, Czech Republic (D.C.); the Division of Gynecologic Oncology (C.M.) and National Cancer Institute-sponsored NRG Oncology (M.A.P.), Washington University School of Medicine, St. Louis; Hanjani Institute for Gynecologic Oncology, Abington Hospital-Jefferson Health, Asplundh Cancer Pavilion, Sidney Kimmel Medical College, Thomas Jefferson University, Willow Grove (M.S.S.), and GSK, Collegeville (M.T., Z.H.) - both in Pennsylvania; the Division of Gynecologic Oncology, Nancy N. and J.C. Lewis Cancer and Research Pavilion, Savannah, GA (S.E.G.); HonorHealth Research Institute, University of Arizona College of Medicine, and Creighton University School of Medicine, Phoenix (B.J.M.), and the Department of Gynecologic Oncology, Arizona Oncology, Tucson (J.B.); the Department of Obstetrics and Gynecology, University of Cincinnati Cancer Center, Cincinnati (T.J.H.), and Ohio State University Comprehensive Cancer Center, Hillard (L.J.C.); GSK, London (S.S., E.Z.); and US Oncology Research, the Woodlands, TX (R.L.C.).

Bhavana Pothuri (B)

From the Department of Oncology, Rigshospitalet, Copenhagen University Hospital, and the Nordic Society of Gynaecological Oncology-Clinical Trial Unit, Copenhagen (M.R.M.), and the Research Unit for General Practice, University of Southern Denmark, Institute of Public Health, Odense (R.C.) - all in Denmark; David Geffen School of Medicine, University of California, Los Angeles, Los Angeles (D.M.C.); the Department of Gynecologic Oncology, Mount Sinai Medical Center, and the Department of Obstetrics and Gynecology, Florida International University, Miami Beach (B.M.S.); the Department of Gynecology, Hungarian National Institute of Oncology, Budapest, Hungary (Z.N.); the Department of Obstetrics and Gynecology, Louisiana State University Health Shreveport, and Willis-Knighton Physician Network, Shreveport (D.B.); the Division of Gynecologic Oncology, McGill University Health Centre, Montreal (L.G.); the Department of Obstetrics and Gynecology, AMITA Adventist Hinsdale Hospital, Hinsdale, IL (S.S.); the University of Turin, A.O. Ordine Mauriziano, Turin (G.V.), and the Gynecologic Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori-Milano, University of Milan, Milan (F.R.) - both in Italy; Indiana University Health Simon Cancer Center, Indianapolis (L.M.L.); the Department of Gynecology and Obstetrics, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany (L.C.H.); Women and Infants Hospital, Providence, RI (A.S.); the Department of Medical Oncology, Erasmus MC Cancer Center, Rotterdam, the Netherlands (I.B.); Oklahoma Cancer Specialists and Research Institute, Tulsa (M.A.G.); Tays Cancer Center and FICAN Mid, Tampere University and Tampere University Hospital, Tampere, Finland (A.A.); New York University Langone Health, New York (B.P.); the Department of Obstetrics and Gynecology, General University Hospital in Prague, First Faculty of Medicine, Charles University, Prague, Czech Republic (D.C.); the Division of Gynecologic Oncology (C.M.) and National Cancer Institute-sponsored NRG Oncology (M.A.P.), Washington University School of Medicine, St. Louis; Hanjani Institute for Gynecologic Oncology, Abington Hospital-Jefferson Health, Asplundh Cancer Pavilion, Sidney Kimmel Medical College, Thomas Jefferson University, Willow Grove (M.S.S.), and GSK, Collegeville (M.T., Z.H.) - both in Pennsylvania; the Division of Gynecologic Oncology, Nancy N. and J.C. Lewis Cancer and Research Pavilion, Savannah, GA (S.E.G.); HonorHealth Research Institute, University of Arizona College of Medicine, and Creighton University School of Medicine, Phoenix (B.J.M.), and the Department of Gynecologic Oncology, Arizona Oncology, Tucson (J.B.); the Department of Obstetrics and Gynecology, University of Cincinnati Cancer Center, Cincinnati (T.J.H.), and Ohio State University Comprehensive Cancer Center, Hillard (L.J.C.); GSK, London (S.S., E.Z.); and US Oncology Research, the Woodlands, TX (R.L.C.).

David Cibula (D)

From the Department of Oncology, Rigshospitalet, Copenhagen University Hospital, and the Nordic Society of Gynaecological Oncology-Clinical Trial Unit, Copenhagen (M.R.M.), and the Research Unit for General Practice, University of Southern Denmark, Institute of Public Health, Odense (R.C.) - all in Denmark; David Geffen School of Medicine, University of California, Los Angeles, Los Angeles (D.M.C.); the Department of Gynecologic Oncology, Mount Sinai Medical Center, and the Department of Obstetrics and Gynecology, Florida International University, Miami Beach (B.M.S.); the Department of Gynecology, Hungarian National Institute of Oncology, Budapest, Hungary (Z.N.); the Department of Obstetrics and Gynecology, Louisiana State University Health Shreveport, and Willis-Knighton Physician Network, Shreveport (D.B.); the Division of Gynecologic Oncology, McGill University Health Centre, Montreal (L.G.); the Department of Obstetrics and Gynecology, AMITA Adventist Hinsdale Hospital, Hinsdale, IL (S.S.); the University of Turin, A.O. Ordine Mauriziano, Turin (G.V.), and the Gynecologic Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori-Milano, University of Milan, Milan (F.R.) - both in Italy; Indiana University Health Simon Cancer Center, Indianapolis (L.M.L.); the Department of Gynecology and Obstetrics, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany (L.C.H.); Women and Infants Hospital, Providence, RI (A.S.); the Department of Medical Oncology, Erasmus MC Cancer Center, Rotterdam, the Netherlands (I.B.); Oklahoma Cancer Specialists and Research Institute, Tulsa (M.A.G.); Tays Cancer Center and FICAN Mid, Tampere University and Tampere University Hospital, Tampere, Finland (A.A.); New York University Langone Health, New York (B.P.); the Department of Obstetrics and Gynecology, General University Hospital in Prague, First Faculty of Medicine, Charles University, Prague, Czech Republic (D.C.); the Division of Gynecologic Oncology (C.M.) and National Cancer Institute-sponsored NRG Oncology (M.A.P.), Washington University School of Medicine, St. Louis; Hanjani Institute for Gynecologic Oncology, Abington Hospital-Jefferson Health, Asplundh Cancer Pavilion, Sidney Kimmel Medical College, Thomas Jefferson University, Willow Grove (M.S.S.), and GSK, Collegeville (M.T., Z.H.) - both in Pennsylvania; the Division of Gynecologic Oncology, Nancy N. and J.C. Lewis Cancer and Research Pavilion, Savannah, GA (S.E.G.); HonorHealth Research Institute, University of Arizona College of Medicine, and Creighton University School of Medicine, Phoenix (B.J.M.), and the Department of Gynecologic Oncology, Arizona Oncology, Tucson (J.B.); the Department of Obstetrics and Gynecology, University of Cincinnati Cancer Center, Cincinnati (T.J.H.), and Ohio State University Comprehensive Cancer Center, Hillard (L.J.C.); GSK, London (S.S., E.Z.); and US Oncology Research, the Woodlands, TX (R.L.C.).

Carolyn McCourt (C)

From the Department of Oncology, Rigshospitalet, Copenhagen University Hospital, and the Nordic Society of Gynaecological Oncology-Clinical Trial Unit, Copenhagen (M.R.M.), and the Research Unit for General Practice, University of Southern Denmark, Institute of Public Health, Odense (R.C.) - all in Denmark; David Geffen School of Medicine, University of California, Los Angeles, Los Angeles (D.M.C.); the Department of Gynecologic Oncology, Mount Sinai Medical Center, and the Department of Obstetrics and Gynecology, Florida International University, Miami Beach (B.M.S.); the Department of Gynecology, Hungarian National Institute of Oncology, Budapest, Hungary (Z.N.); the Department of Obstetrics and Gynecology, Louisiana State University Health Shreveport, and Willis-Knighton Physician Network, Shreveport (D.B.); the Division of Gynecologic Oncology, McGill University Health Centre, Montreal (L.G.); the Department of Obstetrics and Gynecology, AMITA Adventist Hinsdale Hospital, Hinsdale, IL (S.S.); the University of Turin, A.O. Ordine Mauriziano, Turin (G.V.), and the Gynecologic Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori-Milano, University of Milan, Milan (F.R.) - both in Italy; Indiana University Health Simon Cancer Center, Indianapolis (L.M.L.); the Department of Gynecology and Obstetrics, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany (L.C.H.); Women and Infants Hospital, Providence, RI (A.S.); the Department of Medical Oncology, Erasmus MC Cancer Center, Rotterdam, the Netherlands (I.B.); Oklahoma Cancer Specialists and Research Institute, Tulsa (M.A.G.); Tays Cancer Center and FICAN Mid, Tampere University and Tampere University Hospital, Tampere, Finland (A.A.); New York University Langone Health, New York (B.P.); the Department of Obstetrics and Gynecology, General University Hospital in Prague, First Faculty of Medicine, Charles University, Prague, Czech Republic (D.C.); the Division of Gynecologic Oncology (C.M.) and National Cancer Institute-sponsored NRG Oncology (M.A.P.), Washington University School of Medicine, St. Louis; Hanjani Institute for Gynecologic Oncology, Abington Hospital-Jefferson Health, Asplundh Cancer Pavilion, Sidney Kimmel Medical College, Thomas Jefferson University, Willow Grove (M.S.S.), and GSK, Collegeville (M.T., Z.H.) - both in Pennsylvania; the Division of Gynecologic Oncology, Nancy N. and J.C. Lewis Cancer and Research Pavilion, Savannah, GA (S.E.G.); HonorHealth Research Institute, University of Arizona College of Medicine, and Creighton University School of Medicine, Phoenix (B.J.M.), and the Department of Gynecologic Oncology, Arizona Oncology, Tucson (J.B.); the Department of Obstetrics and Gynecology, University of Cincinnati Cancer Center, Cincinnati (T.J.H.), and Ohio State University Comprehensive Cancer Center, Hillard (L.J.C.); GSK, London (S.S., E.Z.); and US Oncology Research, the Woodlands, TX (R.L.C.).

Francesco Raspagliesi (F)

From the Department of Oncology, Rigshospitalet, Copenhagen University Hospital, and the Nordic Society of Gynaecological Oncology-Clinical Trial Unit, Copenhagen (M.R.M.), and the Research Unit for General Practice, University of Southern Denmark, Institute of Public Health, Odense (R.C.) - all in Denmark; David Geffen School of Medicine, University of California, Los Angeles, Los Angeles (D.M.C.); the Department of Gynecologic Oncology, Mount Sinai Medical Center, and the Department of Obstetrics and Gynecology, Florida International University, Miami Beach (B.M.S.); the Department of Gynecology, Hungarian National Institute of Oncology, Budapest, Hungary (Z.N.); the Department of Obstetrics and Gynecology, Louisiana State University Health Shreveport, and Willis-Knighton Physician Network, Shreveport (D.B.); the Division of Gynecologic Oncology, McGill University Health Centre, Montreal (L.G.); the Department of Obstetrics and Gynecology, AMITA Adventist Hinsdale Hospital, Hinsdale, IL (S.S.); the University of Turin, A.O. Ordine Mauriziano, Turin (G.V.), and the Gynecologic Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori-Milano, University of Milan, Milan (F.R.) - both in Italy; Indiana University Health Simon Cancer Center, Indianapolis (L.M.L.); the Department of Gynecology and Obstetrics, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany (L.C.H.); Women and Infants Hospital, Providence, RI (A.S.); the Department of Medical Oncology, Erasmus MC Cancer Center, Rotterdam, the Netherlands (I.B.); Oklahoma Cancer Specialists and Research Institute, Tulsa (M.A.G.); Tays Cancer Center and FICAN Mid, Tampere University and Tampere University Hospital, Tampere, Finland (A.A.); New York University Langone Health, New York (B.P.); the Department of Obstetrics and Gynecology, General University Hospital in Prague, First Faculty of Medicine, Charles University, Prague, Czech Republic (D.C.); the Division of Gynecologic Oncology (C.M.) and National Cancer Institute-sponsored NRG Oncology (M.A.P.), Washington University School of Medicine, St. Louis; Hanjani Institute for Gynecologic Oncology, Abington Hospital-Jefferson Health, Asplundh Cancer Pavilion, Sidney Kimmel Medical College, Thomas Jefferson University, Willow Grove (M.S.S.), and GSK, Collegeville (M.T., Z.H.) - both in Pennsylvania; the Division of Gynecologic Oncology, Nancy N. and J.C. Lewis Cancer and Research Pavilion, Savannah, GA (S.E.G.); HonorHealth Research Institute, University of Arizona College of Medicine, and Creighton University School of Medicine, Phoenix (B.J.M.), and the Department of Gynecologic Oncology, Arizona Oncology, Tucson (J.B.); the Department of Obstetrics and Gynecology, University of Cincinnati Cancer Center, Cincinnati (T.J.H.), and Ohio State University Comprehensive Cancer Center, Hillard (L.J.C.); GSK, London (S.S., E.Z.); and US Oncology Research, the Woodlands, TX (R.L.C.).

Mark S Shahin (MS)

From the Department of Oncology, Rigshospitalet, Copenhagen University Hospital, and the Nordic Society of Gynaecological Oncology-Clinical Trial Unit, Copenhagen (M.R.M.), and the Research Unit for General Practice, University of Southern Denmark, Institute of Public Health, Odense (R.C.) - all in Denmark; David Geffen School of Medicine, University of California, Los Angeles, Los Angeles (D.M.C.); the Department of Gynecologic Oncology, Mount Sinai Medical Center, and the Department of Obstetrics and Gynecology, Florida International University, Miami Beach (B.M.S.); the Department of Gynecology, Hungarian National Institute of Oncology, Budapest, Hungary (Z.N.); the Department of Obstetrics and Gynecology, Louisiana State University Health Shreveport, and Willis-Knighton Physician Network, Shreveport (D.B.); the Division of Gynecologic Oncology, McGill University Health Centre, Montreal (L.G.); the Department of Obstetrics and Gynecology, AMITA Adventist Hinsdale Hospital, Hinsdale, IL (S.S.); the University of Turin, A.O. Ordine Mauriziano, Turin (G.V.), and the Gynecologic Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori-Milano, University of Milan, Milan (F.R.) - both in Italy; Indiana University Health Simon Cancer Center, Indianapolis (L.M.L.); the Department of Gynecology and Obstetrics, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany (L.C.H.); Women and Infants Hospital, Providence, RI (A.S.); the Department of Medical Oncology, Erasmus MC Cancer Center, Rotterdam, the Netherlands (I.B.); Oklahoma Cancer Specialists and Research Institute, Tulsa (M.A.G.); Tays Cancer Center and FICAN Mid, Tampere University and Tampere University Hospital, Tampere, Finland (A.A.); New York University Langone Health, New York (B.P.); the Department of Obstetrics and Gynecology, General University Hospital in Prague, First Faculty of Medicine, Charles University, Prague, Czech Republic (D.C.); the Division of Gynecologic Oncology (C.M.) and National Cancer Institute-sponsored NRG Oncology (M.A.P.), Washington University School of Medicine, St. Louis; Hanjani Institute for Gynecologic Oncology, Abington Hospital-Jefferson Health, Asplundh Cancer Pavilion, Sidney Kimmel Medical College, Thomas Jefferson University, Willow Grove (M.S.S.), and GSK, Collegeville (M.T., Z.H.) - both in Pennsylvania; the Division of Gynecologic Oncology, Nancy N. and J.C. Lewis Cancer and Research Pavilion, Savannah, GA (S.E.G.); HonorHealth Research Institute, University of Arizona College of Medicine, and Creighton University School of Medicine, Phoenix (B.J.M.), and the Department of Gynecologic Oncology, Arizona Oncology, Tucson (J.B.); the Department of Obstetrics and Gynecology, University of Cincinnati Cancer Center, Cincinnati (T.J.H.), and Ohio State University Comprehensive Cancer Center, Hillard (L.J.C.); GSK, London (S.S., E.Z.); and US Oncology Research, the Woodlands, TX (R.L.C.).

Sarah E Gill (SE)

From the Department of Oncology, Rigshospitalet, Copenhagen University Hospital, and the Nordic Society of Gynaecological Oncology-Clinical Trial Unit, Copenhagen (M.R.M.), and the Research Unit for General Practice, University of Southern Denmark, Institute of Public Health, Odense (R.C.) - all in Denmark; David Geffen School of Medicine, University of California, Los Angeles, Los Angeles (D.M.C.); the Department of Gynecologic Oncology, Mount Sinai Medical Center, and the Department of Obstetrics and Gynecology, Florida International University, Miami Beach (B.M.S.); the Department of Gynecology, Hungarian National Institute of Oncology, Budapest, Hungary (Z.N.); the Department of Obstetrics and Gynecology, Louisiana State University Health Shreveport, and Willis-Knighton Physician Network, Shreveport (D.B.); the Division of Gynecologic Oncology, McGill University Health Centre, Montreal (L.G.); the Department of Obstetrics and Gynecology, AMITA Adventist Hinsdale Hospital, Hinsdale, IL (S.S.); the University of Turin, A.O. Ordine Mauriziano, Turin (G.V.), and the Gynecologic Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori-Milano, University of Milan, Milan (F.R.) - both in Italy; Indiana University Health Simon Cancer Center, Indianapolis (L.M.L.); the Department of Gynecology and Obstetrics, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany (L.C.H.); Women and Infants Hospital, Providence, RI (A.S.); the Department of Medical Oncology, Erasmus MC Cancer Center, Rotterdam, the Netherlands (I.B.); Oklahoma Cancer Specialists and Research Institute, Tulsa (M.A.G.); Tays Cancer Center and FICAN Mid, Tampere University and Tampere University Hospital, Tampere, Finland (A.A.); New York University Langone Health, New York (B.P.); the Department of Obstetrics and Gynecology, General University Hospital in Prague, First Faculty of Medicine, Charles University, Prague, Czech Republic (D.C.); the Division of Gynecologic Oncology (C.M.) and National Cancer Institute-sponsored NRG Oncology (M.A.P.), Washington University School of Medicine, St. Louis; Hanjani Institute for Gynecologic Oncology, Abington Hospital-Jefferson Health, Asplundh Cancer Pavilion, Sidney Kimmel Medical College, Thomas Jefferson University, Willow Grove (M.S.S.), and GSK, Collegeville (M.T., Z.H.) - both in Pennsylvania; the Division of Gynecologic Oncology, Nancy N. and J.C. Lewis Cancer and Research Pavilion, Savannah, GA (S.E.G.); HonorHealth Research Institute, University of Arizona College of Medicine, and Creighton University School of Medicine, Phoenix (B.J.M.), and the Department of Gynecologic Oncology, Arizona Oncology, Tucson (J.B.); the Department of Obstetrics and Gynecology, University of Cincinnati Cancer Center, Cincinnati (T.J.H.), and Ohio State University Comprehensive Cancer Center, Hillard (L.J.C.); GSK, London (S.S., E.Z.); and US Oncology Research, the Woodlands, TX (R.L.C.).

Bradley J Monk (BJ)

From the Department of Oncology, Rigshospitalet, Copenhagen University Hospital, and the Nordic Society of Gynaecological Oncology-Clinical Trial Unit, Copenhagen (M.R.M.), and the Research Unit for General Practice, University of Southern Denmark, Institute of Public Health, Odense (R.C.) - all in Denmark; David Geffen School of Medicine, University of California, Los Angeles, Los Angeles (D.M.C.); the Department of Gynecologic Oncology, Mount Sinai Medical Center, and the Department of Obstetrics and Gynecology, Florida International University, Miami Beach (B.M.S.); the Department of Gynecology, Hungarian National Institute of Oncology, Budapest, Hungary (Z.N.); the Department of Obstetrics and Gynecology, Louisiana State University Health Shreveport, and Willis-Knighton Physician Network, Shreveport (D.B.); the Division of Gynecologic Oncology, McGill University Health Centre, Montreal (L.G.); the Department of Obstetrics and Gynecology, AMITA Adventist Hinsdale Hospital, Hinsdale, IL (S.S.); the University of Turin, A.O. Ordine Mauriziano, Turin (G.V.), and the Gynecologic Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori-Milano, University of Milan, Milan (F.R.) - both in Italy; Indiana University Health Simon Cancer Center, Indianapolis (L.M.L.); the Department of Gynecology and Obstetrics, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany (L.C.H.); Women and Infants Hospital, Providence, RI (A.S.); the Department of Medical Oncology, Erasmus MC Cancer Center, Rotterdam, the Netherlands (I.B.); Oklahoma Cancer Specialists and Research Institute, Tulsa (M.A.G.); Tays Cancer Center and FICAN Mid, Tampere University and Tampere University Hospital, Tampere, Finland (A.A.); New York University Langone Health, New York (B.P.); the Department of Obstetrics and Gynecology, General University Hospital in Prague, First Faculty of Medicine, Charles University, Prague, Czech Republic (D.C.); the Division of Gynecologic Oncology (C.M.) and National Cancer Institute-sponsored NRG Oncology (M.A.P.), Washington University School of Medicine, St. Louis; Hanjani Institute for Gynecologic Oncology, Abington Hospital-Jefferson Health, Asplundh Cancer Pavilion, Sidney Kimmel Medical College, Thomas Jefferson University, Willow Grove (M.S.S.), and GSK, Collegeville (M.T., Z.H.) - both in Pennsylvania; the Division of Gynecologic Oncology, Nancy N. and J.C. Lewis Cancer and Research Pavilion, Savannah, GA (S.E.G.); HonorHealth Research Institute, University of Arizona College of Medicine, and Creighton University School of Medicine, Phoenix (B.J.M.), and the Department of Gynecologic Oncology, Arizona Oncology, Tucson (J.B.); the Department of Obstetrics and Gynecology, University of Cincinnati Cancer Center, Cincinnati (T.J.H.), and Ohio State University Comprehensive Cancer Center, Hillard (L.J.C.); GSK, London (S.S., E.Z.); and US Oncology Research, the Woodlands, TX (R.L.C.).

Joseph Buscema (J)

From the Department of Oncology, Rigshospitalet, Copenhagen University Hospital, and the Nordic Society of Gynaecological Oncology-Clinical Trial Unit, Copenhagen (M.R.M.), and the Research Unit for General Practice, University of Southern Denmark, Institute of Public Health, Odense (R.C.) - all in Denmark; David Geffen School of Medicine, University of California, Los Angeles, Los Angeles (D.M.C.); the Department of Gynecologic Oncology, Mount Sinai Medical Center, and the Department of Obstetrics and Gynecology, Florida International University, Miami Beach (B.M.S.); the Department of Gynecology, Hungarian National Institute of Oncology, Budapest, Hungary (Z.N.); the Department of Obstetrics and Gynecology, Louisiana State University Health Shreveport, and Willis-Knighton Physician Network, Shreveport (D.B.); the Division of Gynecologic Oncology, McGill University Health Centre, Montreal (L.G.); the Department of Obstetrics and Gynecology, AMITA Adventist Hinsdale Hospital, Hinsdale, IL (S.S.); the University of Turin, A.O. Ordine Mauriziano, Turin (G.V.), and the Gynecologic Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori-Milano, University of Milan, Milan (F.R.) - both in Italy; Indiana University Health Simon Cancer Center, Indianapolis (L.M.L.); the Department of Gynecology and Obstetrics, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany (L.C.H.); Women and Infants Hospital, Providence, RI (A.S.); the Department of Medical Oncology, Erasmus MC Cancer Center, Rotterdam, the Netherlands (I.B.); Oklahoma Cancer Specialists and Research Institute, Tulsa (M.A.G.); Tays Cancer Center and FICAN Mid, Tampere University and Tampere University Hospital, Tampere, Finland (A.A.); New York University Langone Health, New York (B.P.); the Department of Obstetrics and Gynecology, General University Hospital in Prague, First Faculty of Medicine, Charles University, Prague, Czech Republic (D.C.); the Division of Gynecologic Oncology (C.M.) and National Cancer Institute-sponsored NRG Oncology (M.A.P.), Washington University School of Medicine, St. Louis; Hanjani Institute for Gynecologic Oncology, Abington Hospital-Jefferson Health, Asplundh Cancer Pavilion, Sidney Kimmel Medical College, Thomas Jefferson University, Willow Grove (M.S.S.), and GSK, Collegeville (M.T., Z.H.) - both in Pennsylvania; the Division of Gynecologic Oncology, Nancy N. and J.C. Lewis Cancer and Research Pavilion, Savannah, GA (S.E.G.); HonorHealth Research Institute, University of Arizona College of Medicine, and Creighton University School of Medicine, Phoenix (B.J.M.), and the Department of Gynecologic Oncology, Arizona Oncology, Tucson (J.B.); the Department of Obstetrics and Gynecology, University of Cincinnati Cancer Center, Cincinnati (T.J.H.), and Ohio State University Comprehensive Cancer Center, Hillard (L.J.C.); GSK, London (S.S., E.Z.); and US Oncology Research, the Woodlands, TX (R.L.C.).

Thomas J Herzog (TJ)

From the Department of Oncology, Rigshospitalet, Copenhagen University Hospital, and the Nordic Society of Gynaecological Oncology-Clinical Trial Unit, Copenhagen (M.R.M.), and the Research Unit for General Practice, University of Southern Denmark, Institute of Public Health, Odense (R.C.) - all in Denmark; David Geffen School of Medicine, University of California, Los Angeles, Los Angeles (D.M.C.); the Department of Gynecologic Oncology, Mount Sinai Medical Center, and the Department of Obstetrics and Gynecology, Florida International University, Miami Beach (B.M.S.); the Department of Gynecology, Hungarian National Institute of Oncology, Budapest, Hungary (Z.N.); the Department of Obstetrics and Gynecology, Louisiana State University Health Shreveport, and Willis-Knighton Physician Network, Shreveport (D.B.); the Division of Gynecologic Oncology, McGill University Health Centre, Montreal (L.G.); the Department of Obstetrics and Gynecology, AMITA Adventist Hinsdale Hospital, Hinsdale, IL (S.S.); the University of Turin, A.O. Ordine Mauriziano, Turin (G.V.), and the Gynecologic Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori-Milano, University of Milan, Milan (F.R.) - both in Italy; Indiana University Health Simon Cancer Center, Indianapolis (L.M.L.); the Department of Gynecology and Obstetrics, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany (L.C.H.); Women and Infants Hospital, Providence, RI (A.S.); the Department of Medical Oncology, Erasmus MC Cancer Center, Rotterdam, the Netherlands (I.B.); Oklahoma Cancer Specialists and Research Institute, Tulsa (M.A.G.); Tays Cancer Center and FICAN Mid, Tampere University and Tampere University Hospital, Tampere, Finland (A.A.); New York University Langone Health, New York (B.P.); the Department of Obstetrics and Gynecology, General University Hospital in Prague, First Faculty of Medicine, Charles University, Prague, Czech Republic (D.C.); the Division of Gynecologic Oncology (C.M.) and National Cancer Institute-sponsored NRG Oncology (M.A.P.), Washington University School of Medicine, St. Louis; Hanjani Institute for Gynecologic Oncology, Abington Hospital-Jefferson Health, Asplundh Cancer Pavilion, Sidney Kimmel Medical College, Thomas Jefferson University, Willow Grove (M.S.S.), and GSK, Collegeville (M.T., Z.H.) - both in Pennsylvania; the Division of Gynecologic Oncology, Nancy N. and J.C. Lewis Cancer and Research Pavilion, Savannah, GA (S.E.G.); HonorHealth Research Institute, University of Arizona College of Medicine, and Creighton University School of Medicine, Phoenix (B.J.M.), and the Department of Gynecologic Oncology, Arizona Oncology, Tucson (J.B.); the Department of Obstetrics and Gynecology, University of Cincinnati Cancer Center, Cincinnati (T.J.H.), and Ohio State University Comprehensive Cancer Center, Hillard (L.J.C.); GSK, London (S.S., E.Z.); and US Oncology Research, the Woodlands, TX (R.L.C.).

Larry J Copeland (LJ)

From the Department of Oncology, Rigshospitalet, Copenhagen University Hospital, and the Nordic Society of Gynaecological Oncology-Clinical Trial Unit, Copenhagen (M.R.M.), and the Research Unit for General Practice, University of Southern Denmark, Institute of Public Health, Odense (R.C.) - all in Denmark; David Geffen School of Medicine, University of California, Los Angeles, Los Angeles (D.M.C.); the Department of Gynecologic Oncology, Mount Sinai Medical Center, and the Department of Obstetrics and Gynecology, Florida International University, Miami Beach (B.M.S.); the Department of Gynecology, Hungarian National Institute of Oncology, Budapest, Hungary (Z.N.); the Department of Obstetrics and Gynecology, Louisiana State University Health Shreveport, and Willis-Knighton Physician Network, Shreveport (D.B.); the Division of Gynecologic Oncology, McGill University Health Centre, Montreal (L.G.); the Department of Obstetrics and Gynecology, AMITA Adventist Hinsdale Hospital, Hinsdale, IL (S.S.); the University of Turin, A.O. Ordine Mauriziano, Turin (G.V.), and the Gynecologic Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori-Milano, University of Milan, Milan (F.R.) - both in Italy; Indiana University Health Simon Cancer Center, Indianapolis (L.M.L.); the Department of Gynecology and Obstetrics, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany (L.C.H.); Women and Infants Hospital, Providence, RI (A.S.); the Department of Medical Oncology, Erasmus MC Cancer Center, Rotterdam, the Netherlands (I.B.); Oklahoma Cancer Specialists and Research Institute, Tulsa (M.A.G.); Tays Cancer Center and FICAN Mid, Tampere University and Tampere University Hospital, Tampere, Finland (A.A.); New York University Langone Health, New York (B.P.); the Department of Obstetrics and Gynecology, General University Hospital in Prague, First Faculty of Medicine, Charles University, Prague, Czech Republic (D.C.); the Division of Gynecologic Oncology (C.M.) and National Cancer Institute-sponsored NRG Oncology (M.A.P.), Washington University School of Medicine, St. Louis; Hanjani Institute for Gynecologic Oncology, Abington Hospital-Jefferson Health, Asplundh Cancer Pavilion, Sidney Kimmel Medical College, Thomas Jefferson University, Willow Grove (M.S.S.), and GSK, Collegeville (M.T., Z.H.) - both in Pennsylvania; the Division of Gynecologic Oncology, Nancy N. and J.C. Lewis Cancer and Research Pavilion, Savannah, GA (S.E.G.); HonorHealth Research Institute, University of Arizona College of Medicine, and Creighton University School of Medicine, Phoenix (B.J.M.), and the Department of Gynecologic Oncology, Arizona Oncology, Tucson (J.B.); the Department of Obstetrics and Gynecology, University of Cincinnati Cancer Center, Cincinnati (T.J.H.), and Ohio State University Comprehensive Cancer Center, Hillard (L.J.C.); GSK, London (S.S., E.Z.); and US Oncology Research, the Woodlands, TX (R.L.C.).

Min Tian (M)

From the Department of Oncology, Rigshospitalet, Copenhagen University Hospital, and the Nordic Society of Gynaecological Oncology-Clinical Trial Unit, Copenhagen (M.R.M.), and the Research Unit for General Practice, University of Southern Denmark, Institute of Public Health, Odense (R.C.) - all in Denmark; David Geffen School of Medicine, University of California, Los Angeles, Los Angeles (D.M.C.); the Department of Gynecologic Oncology, Mount Sinai Medical Center, and the Department of Obstetrics and Gynecology, Florida International University, Miami Beach (B.M.S.); the Department of Gynecology, Hungarian National Institute of Oncology, Budapest, Hungary (Z.N.); the Department of Obstetrics and Gynecology, Louisiana State University Health Shreveport, and Willis-Knighton Physician Network, Shreveport (D.B.); the Division of Gynecologic Oncology, McGill University Health Centre, Montreal (L.G.); the Department of Obstetrics and Gynecology, AMITA Adventist Hinsdale Hospital, Hinsdale, IL (S.S.); the University of Turin, A.O. Ordine Mauriziano, Turin (G.V.), and the Gynecologic Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori-Milano, University of Milan, Milan (F.R.) - both in Italy; Indiana University Health Simon Cancer Center, Indianapolis (L.M.L.); the Department of Gynecology and Obstetrics, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany (L.C.H.); Women and Infants Hospital, Providence, RI (A.S.); the Department of Medical Oncology, Erasmus MC Cancer Center, Rotterdam, the Netherlands (I.B.); Oklahoma Cancer Specialists and Research Institute, Tulsa (M.A.G.); Tays Cancer Center and FICAN Mid, Tampere University and Tampere University Hospital, Tampere, Finland (A.A.); New York University Langone Health, New York (B.P.); the Department of Obstetrics and Gynecology, General University Hospital in Prague, First Faculty of Medicine, Charles University, Prague, Czech Republic (D.C.); the Division of Gynecologic Oncology (C.M.) and National Cancer Institute-sponsored NRG Oncology (M.A.P.), Washington University School of Medicine, St. Louis; Hanjani Institute for Gynecologic Oncology, Abington Hospital-Jefferson Health, Asplundh Cancer Pavilion, Sidney Kimmel Medical College, Thomas Jefferson University, Willow Grove (M.S.S.), and GSK, Collegeville (M.T., Z.H.) - both in Pennsylvania; the Division of Gynecologic Oncology, Nancy N. and J.C. Lewis Cancer and Research Pavilion, Savannah, GA (S.E.G.); HonorHealth Research Institute, University of Arizona College of Medicine, and Creighton University School of Medicine, Phoenix (B.J.M.), and the Department of Gynecologic Oncology, Arizona Oncology, Tucson (J.B.); the Department of Obstetrics and Gynecology, University of Cincinnati Cancer Center, Cincinnati (T.J.H.), and Ohio State University Comprehensive Cancer Center, Hillard (L.J.C.); GSK, London (S.S., E.Z.); and US Oncology Research, the Woodlands, TX (R.L.C.).

Zangdong He (Z)

From the Department of Oncology, Rigshospitalet, Copenhagen University Hospital, and the Nordic Society of Gynaecological Oncology-Clinical Trial Unit, Copenhagen (M.R.M.), and the Research Unit for General Practice, University of Southern Denmark, Institute of Public Health, Odense (R.C.) - all in Denmark; David Geffen School of Medicine, University of California, Los Angeles, Los Angeles (D.M.C.); the Department of Gynecologic Oncology, Mount Sinai Medical Center, and the Department of Obstetrics and Gynecology, Florida International University, Miami Beach (B.M.S.); the Department of Gynecology, Hungarian National Institute of Oncology, Budapest, Hungary (Z.N.); the Department of Obstetrics and Gynecology, Louisiana State University Health Shreveport, and Willis-Knighton Physician Network, Shreveport (D.B.); the Division of Gynecologic Oncology, McGill University Health Centre, Montreal (L.G.); the Department of Obstetrics and Gynecology, AMITA Adventist Hinsdale Hospital, Hinsdale, IL (S.S.); the University of Turin, A.O. Ordine Mauriziano, Turin (G.V.), and the Gynecologic Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori-Milano, University of Milan, Milan (F.R.) - both in Italy; Indiana University Health Simon Cancer Center, Indianapolis (L.M.L.); the Department of Gynecology and Obstetrics, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany (L.C.H.); Women and Infants Hospital, Providence, RI (A.S.); the Department of Medical Oncology, Erasmus MC Cancer Center, Rotterdam, the Netherlands (I.B.); Oklahoma Cancer Specialists and Research Institute, Tulsa (M.A.G.); Tays Cancer Center and FICAN Mid, Tampere University and Tampere University Hospital, Tampere, Finland (A.A.); New York University Langone Health, New York (B.P.); the Department of Obstetrics and Gynecology, General University Hospital in Prague, First Faculty of Medicine, Charles University, Prague, Czech Republic (D.C.); the Division of Gynecologic Oncology (C.M.) and National Cancer Institute-sponsored NRG Oncology (M.A.P.), Washington University School of Medicine, St. Louis; Hanjani Institute for Gynecologic Oncology, Abington Hospital-Jefferson Health, Asplundh Cancer Pavilion, Sidney Kimmel Medical College, Thomas Jefferson University, Willow Grove (M.S.S.), and GSK, Collegeville (M.T., Z.H.) - both in Pennsylvania; the Division of Gynecologic Oncology, Nancy N. and J.C. Lewis Cancer and Research Pavilion, Savannah, GA (S.E.G.); HonorHealth Research Institute, University of Arizona College of Medicine, and Creighton University School of Medicine, Phoenix (B.J.M.), and the Department of Gynecologic Oncology, Arizona Oncology, Tucson (J.B.); the Department of Obstetrics and Gynecology, University of Cincinnati Cancer Center, Cincinnati (T.J.H.), and Ohio State University Comprehensive Cancer Center, Hillard (L.J.C.); GSK, London (S.S., E.Z.); and US Oncology Research, the Woodlands, TX (R.L.C.).

Shadi Stevens (S)

From the Department of Oncology, Rigshospitalet, Copenhagen University Hospital, and the Nordic Society of Gynaecological Oncology-Clinical Trial Unit, Copenhagen (M.R.M.), and the Research Unit for General Practice, University of Southern Denmark, Institute of Public Health, Odense (R.C.) - all in Denmark; David Geffen School of Medicine, University of California, Los Angeles, Los Angeles (D.M.C.); the Department of Gynecologic Oncology, Mount Sinai Medical Center, and the Department of Obstetrics and Gynecology, Florida International University, Miami Beach (B.M.S.); the Department of Gynecology, Hungarian National Institute of Oncology, Budapest, Hungary (Z.N.); the Department of Obstetrics and Gynecology, Louisiana State University Health Shreveport, and Willis-Knighton Physician Network, Shreveport (D.B.); the Division of Gynecologic Oncology, McGill University Health Centre, Montreal (L.G.); the Department of Obstetrics and Gynecology, AMITA Adventist Hinsdale Hospital, Hinsdale, IL (S.S.); the University of Turin, A.O. Ordine Mauriziano, Turin (G.V.), and the Gynecologic Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori-Milano, University of Milan, Milan (F.R.) - both in Italy; Indiana University Health Simon Cancer Center, Indianapolis (L.M.L.); the Department of Gynecology and Obstetrics, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany (L.C.H.); Women and Infants Hospital, Providence, RI (A.S.); the Department of Medical Oncology, Erasmus MC Cancer Center, Rotterdam, the Netherlands (I.B.); Oklahoma Cancer Specialists and Research Institute, Tulsa (M.A.G.); Tays Cancer Center and FICAN Mid, Tampere University and Tampere University Hospital, Tampere, Finland (A.A.); New York University Langone Health, New York (B.P.); the Department of Obstetrics and Gynecology, General University Hospital in Prague, First Faculty of Medicine, Charles University, Prague, Czech Republic (D.C.); the Division of Gynecologic Oncology (C.M.) and National Cancer Institute-sponsored NRG Oncology (M.A.P.), Washington University School of Medicine, St. Louis; Hanjani Institute for Gynecologic Oncology, Abington Hospital-Jefferson Health, Asplundh Cancer Pavilion, Sidney Kimmel Medical College, Thomas Jefferson University, Willow Grove (M.S.S.), and GSK, Collegeville (M.T., Z.H.) - both in Pennsylvania; the Division of Gynecologic Oncology, Nancy N. and J.C. Lewis Cancer and Research Pavilion, Savannah, GA (S.E.G.); HonorHealth Research Institute, University of Arizona College of Medicine, and Creighton University School of Medicine, Phoenix (B.J.M.), and the Department of Gynecologic Oncology, Arizona Oncology, Tucson (J.B.); the Department of Obstetrics and Gynecology, University of Cincinnati Cancer Center, Cincinnati (T.J.H.), and Ohio State University Comprehensive Cancer Center, Hillard (L.J.C.); GSK, London (S.S., E.Z.); and US Oncology Research, the Woodlands, TX (R.L.C.).

Eleftherios Zografos (E)

From the Department of Oncology, Rigshospitalet, Copenhagen University Hospital, and the Nordic Society of Gynaecological Oncology-Clinical Trial Unit, Copenhagen (M.R.M.), and the Research Unit for General Practice, University of Southern Denmark, Institute of Public Health, Odense (R.C.) - all in Denmark; David Geffen School of Medicine, University of California, Los Angeles, Los Angeles (D.M.C.); the Department of Gynecologic Oncology, Mount Sinai Medical Center, and the Department of Obstetrics and Gynecology, Florida International University, Miami Beach (B.M.S.); the Department of Gynecology, Hungarian National Institute of Oncology, Budapest, Hungary (Z.N.); the Department of Obstetrics and Gynecology, Louisiana State University Health Shreveport, and Willis-Knighton Physician Network, Shreveport (D.B.); the Division of Gynecologic Oncology, McGill University Health Centre, Montreal (L.G.); the Department of Obstetrics and Gynecology, AMITA Adventist Hinsdale Hospital, Hinsdale, IL (S.S.); the University of Turin, A.O. Ordine Mauriziano, Turin (G.V.), and the Gynecologic Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori-Milano, University of Milan, Milan (F.R.) - both in Italy; Indiana University Health Simon Cancer Center, Indianapolis (L.M.L.); the Department of Gynecology and Obstetrics, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany (L.C.H.); Women and Infants Hospital, Providence, RI (A.S.); the Department of Medical Oncology, Erasmus MC Cancer Center, Rotterdam, the Netherlands (I.B.); Oklahoma Cancer Specialists and Research Institute, Tulsa (M.A.G.); Tays Cancer Center and FICAN Mid, Tampere University and Tampere University Hospital, Tampere, Finland (A.A.); New York University Langone Health, New York (B.P.); the Department of Obstetrics and Gynecology, General University Hospital in Prague, First Faculty of Medicine, Charles University, Prague, Czech Republic (D.C.); the Division of Gynecologic Oncology (C.M.) and National Cancer Institute-sponsored NRG Oncology (M.A.P.), Washington University School of Medicine, St. Louis; Hanjani Institute for Gynecologic Oncology, Abington Hospital-Jefferson Health, Asplundh Cancer Pavilion, Sidney Kimmel Medical College, Thomas Jefferson University, Willow Grove (M.S.S.), and GSK, Collegeville (M.T., Z.H.) - both in Pennsylvania; the Division of Gynecologic Oncology, Nancy N. and J.C. Lewis Cancer and Research Pavilion, Savannah, GA (S.E.G.); HonorHealth Research Institute, University of Arizona College of Medicine, and Creighton University School of Medicine, Phoenix (B.J.M.), and the Department of Gynecologic Oncology, Arizona Oncology, Tucson (J.B.); the Department of Obstetrics and Gynecology, University of Cincinnati Cancer Center, Cincinnati (T.J.H.), and Ohio State University Comprehensive Cancer Center, Hillard (L.J.C.); GSK, London (S.S., E.Z.); and US Oncology Research, the Woodlands, TX (R.L.C.).

Robert L Coleman (RL)

From the Department of Oncology, Rigshospitalet, Copenhagen University Hospital, and the Nordic Society of Gynaecological Oncology-Clinical Trial Unit, Copenhagen (M.R.M.), and the Research Unit for General Practice, University of Southern Denmark, Institute of Public Health, Odense (R.C.) - all in Denmark; David Geffen School of Medicine, University of California, Los Angeles, Los Angeles (D.M.C.); the Department of Gynecologic Oncology, Mount Sinai Medical Center, and the Department of Obstetrics and Gynecology, Florida International University, Miami Beach (B.M.S.); the Department of Gynecology, Hungarian National Institute of Oncology, Budapest, Hungary (Z.N.); the Department of Obstetrics and Gynecology, Louisiana State University Health Shreveport, and Willis-Knighton Physician Network, Shreveport (D.B.); the Division of Gynecologic Oncology, McGill University Health Centre, Montreal (L.G.); the Department of Obstetrics and Gynecology, AMITA Adventist Hinsdale Hospital, Hinsdale, IL (S.S.); the University of Turin, A.O. Ordine Mauriziano, Turin (G.V.), and the Gynecologic Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori-Milano, University of Milan, Milan (F.R.) - both in Italy; Indiana University Health Simon Cancer Center, Indianapolis (L.M.L.); the Department of Gynecology and Obstetrics, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany (L.C.H.); Women and Infants Hospital, Providence, RI (A.S.); the Department of Medical Oncology, Erasmus MC Cancer Center, Rotterdam, the Netherlands (I.B.); Oklahoma Cancer Specialists and Research Institute, Tulsa (M.A.G.); Tays Cancer Center and FICAN Mid, Tampere University and Tampere University Hospital, Tampere, Finland (A.A.); New York University Langone Health, New York (B.P.); the Department of Obstetrics and Gynecology, General University Hospital in Prague, First Faculty of Medicine, Charles University, Prague, Czech Republic (D.C.); the Division of Gynecologic Oncology (C.M.) and National Cancer Institute-sponsored NRG Oncology (M.A.P.), Washington University School of Medicine, St. Louis; Hanjani Institute for Gynecologic Oncology, Abington Hospital-Jefferson Health, Asplundh Cancer Pavilion, Sidney Kimmel Medical College, Thomas Jefferson University, Willow Grove (M.S.S.), and GSK, Collegeville (M.T., Z.H.) - both in Pennsylvania; the Division of Gynecologic Oncology, Nancy N. and J.C. Lewis Cancer and Research Pavilion, Savannah, GA (S.E.G.); HonorHealth Research Institute, University of Arizona College of Medicine, and Creighton University School of Medicine, Phoenix (B.J.M.), and the Department of Gynecologic Oncology, Arizona Oncology, Tucson (J.B.); the Department of Obstetrics and Gynecology, University of Cincinnati Cancer Center, Cincinnati (T.J.H.), and Ohio State University Comprehensive Cancer Center, Hillard (L.J.C.); GSK, London (S.S., E.Z.); and US Oncology Research, the Woodlands, TX (R.L.C.).

Matthew A Powell (MA)

From the Department of Oncology, Rigshospitalet, Copenhagen University Hospital, and the Nordic Society of Gynaecological Oncology-Clinical Trial Unit, Copenhagen (M.R.M.), and the Research Unit for General Practice, University of Southern Denmark, Institute of Public Health, Odense (R.C.) - all in Denmark; David Geffen School of Medicine, University of California, Los Angeles, Los Angeles (D.M.C.); the Department of Gynecologic Oncology, Mount Sinai Medical Center, and the Department of Obstetrics and Gynecology, Florida International University, Miami Beach (B.M.S.); the Department of Gynecology, Hungarian National Institute of Oncology, Budapest, Hungary (Z.N.); the Department of Obstetrics and Gynecology, Louisiana State University Health Shreveport, and Willis-Knighton Physician Network, Shreveport (D.B.); the Division of Gynecologic Oncology, McGill University Health Centre, Montreal (L.G.); the Department of Obstetrics and Gynecology, AMITA Adventist Hinsdale Hospital, Hinsdale, IL (S.S.); the University of Turin, A.O. Ordine Mauriziano, Turin (G.V.), and the Gynecologic Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori-Milano, University of Milan, Milan (F.R.) - both in Italy; Indiana University Health Simon Cancer Center, Indianapolis (L.M.L.); the Department of Gynecology and Obstetrics, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany (L.C.H.); Women and Infants Hospital, Providence, RI (A.S.); the Department of Medical Oncology, Erasmus MC Cancer Center, Rotterdam, the Netherlands (I.B.); Oklahoma Cancer Specialists and Research Institute, Tulsa (M.A.G.); Tays Cancer Center and FICAN Mid, Tampere University and Tampere University Hospital, Tampere, Finland (A.A.); New York University Langone Health, New York (B.P.); the Department of Obstetrics and Gynecology, General University Hospital in Prague, First Faculty of Medicine, Charles University, Prague, Czech Republic (D.C.); the Division of Gynecologic Oncology (C.M.) and National Cancer Institute-sponsored NRG Oncology (M.A.P.), Washington University School of Medicine, St. Louis; Hanjani Institute for Gynecologic Oncology, Abington Hospital-Jefferson Health, Asplundh Cancer Pavilion, Sidney Kimmel Medical College, Thomas Jefferson University, Willow Grove (M.S.S.), and GSK, Collegeville (M.T., Z.H.) - both in Pennsylvania; the Division of Gynecologic Oncology, Nancy N. and J.C. Lewis Cancer and Research Pavilion, Savannah, GA (S.E.G.); HonorHealth Research Institute, University of Arizona College of Medicine, and Creighton University School of Medicine, Phoenix (B.J.M.), and the Department of Gynecologic Oncology, Arizona Oncology, Tucson (J.B.); the Department of Obstetrics and Gynecology, University of Cincinnati Cancer Center, Cincinnati (T.J.H.), and Ohio State University Comprehensive Cancer Center, Hillard (L.J.C.); GSK, London (S.S., E.Z.); and US Oncology Research, the Woodlands, TX (R.L.C.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Dostarlimab for Primary Advanced or Recurrent...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › Anticorps monoclonaux humanisés › Dostarlimab for Primary Advanced or Recurrent...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Association de médicaments › Protocoles de polychimiothérapie antinéoplasique › Dostarlimab for Primary Advanced or Recurrent...
questionsmedicales.fr › Composés chimiques organiques › Complexes de coordination › Carboplatine › Dostarlimab for Primary Advanced or Recurrent...
questionsmedicales.fr › Phénomènes génétiques › Réparation de l'ADN › Réparation de mésappariement de l'ADN › Dostarlimab for Primary Advanced or Recurrent...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Méthodologie en recherche épidémiologique › Méthode en double aveugle › Dostarlimab for Primary Advanced or Recurrent...
questionsmedicales.fr › Maladies urogénitales › Tumeurs de l'appareil urogénital › Tumeurs de l'appareil génital féminin › Tumeurs de l'utérus › Tumeurs de l'endomètre › Dostarlimab for Primary Advanced or Recurrent...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › Antinéoplasiques immunologiques › Inhibiteurs de points de contrôle immunitaires › Dostarlimab for Primary Advanced or Recurrent...
questionsmedicales.fr › Phénomènes génétiques › Instabilité du génome › Instabilité des microsatellites › Dostarlimab for Primary Advanced or Recurrent...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Processus néoplasiques › Récidive tumorale locale › Dostarlimab for Primary Advanced or Recurrent...
questionsmedicales.fr › Composés chimiques organiques › Hydrocarbures › Terpènes › Diterpènes › Taxoïdes › Paclitaxel › Dostarlimab for Primary Advanced or Recurrent...